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Abstract
Background: Congenital diaphragmatic hernia (CDH) is a prenatal defect in 
the integrity of the developing diaphragm, which results in pulmonary 
hypoplasia (PH) with alveolar immaturity. PH leads to life-threatening 
respiratory insufficiency at birth, thus remaining a major cause of neonatal 
mortality and long-term morbidity in CDH. Lipid-containing interstitial 
fibroblasts (LIFs) are critically important for fetal lung growth by stimulating 
alveolarization and surfactant phospholipid production in alveolar epithelial 
cells type II (AECII), which in turn increases alveolar maturation. Thymocyte 
antigen 1 (Thy-1) is a strongly expressed cell surface protein in LIFs, which 
plays a key role in alveolar lipid homeostasis by upregulating adipocyte 
differentiation-related protein (Adrp). Adrp is necessary for the intracellular 
uptake of neutral lipids into LIFs and their transport to AECII. Furthermore, 
LIFs express leptin (Lep), which binds to its receptor (Lep-R) on AECII, thus 
stimulating de novo synthesis and secretion of surfactant proteins.  
Objectives: As Thy-1-/- knockouts show a phenotype similar to PH in human 
CDH with impaired alveolar development and reduced proliferation of LIFs, 
one objective of this study was to identify disruptions in Thy-1 signaling in 
hypoplastic rat lungs with toxicological induced CDH, which may have an 
adverse effect on the expression and lipid content of pulmonary LIFs. In 
addition, as it has been demonstrated that retinoids positively affect the 
proliferation of LIFs and expression of Lep and Lep-R in developing rat 
lungs, another objective was to investigate if prenatal administration of all-
trans retinoic acid (ATRA) may have the potential to attenuate PH in this 
rodent CDH model by improving fetal alveolarization and surfactant 
production.  
Material and methods: Time-mated rats received either nitrofen or vehicle 
via oral-gastric lavage on embryonic day 9.5 (E9.5). For the first objective of 
this work, fetuses were sacrificed on E21.5, and dissected lungs were 
divided into controls (n=28) and CDH-associated PH (n=28). For the second 
objective, control and nitrofen-exposed dams were randomly assigned to 
either intraperitoneal ATRA (5 mg/kg/d) or placebo administration on E18.5, 
E19.5 and E20.5. Fetal lungs were harvested on E21.5, and divided into 
Control+Placebo (n=32), Control+ATRA (n=32), Nitrofen+Placebo (n=32) 
and Nitrofen+ATRA (n=32). Pulmonary gene expression levels of Thy-1,
Adrp, Lep and Lep-R were determined by qRT-PCR. Adrp, Lep and Lep-R
immunohistochemistry was combined with oil red O staining to assess 
5 
pulmonary protein expression and lipid content. Immunofluorescence double 
staining was performed to evaluate pulmonary LIF expression and 
localization by confocal laser scanning microscopy. Alveolarization was 
investigated using stereo- and morphometric analysis techniques. Surfactant 
phospholipid synthesis was analyzed by labeling for surfactant protein B (SP-
B). 
Results: Relative mRNA expression of Thy-1 and Adrp was significantly 
downregulated in hypoplastic rat lungs with nitrofen-induced CDH. Confocal 
laser scanning microscopy confirmed markedly decreased Thy-1
immunoflurescence in pulmonary LIFs of nitrofen-exposed fetuses with CDH, 
which was associated with markedly reduced cytoplasmatic lipid inclusions. 
Adrp immunoreactivity was clearly diminished in specimens with CDH-
associated PH, which was accompanied by impaired alveolar mesenchymal 
cell differentiation and overall reduction of LIFs. Maternal application of 
ATRA resulted in a significantly increased lung-to-body weight ratio of 
nitrofen-exposed fetuses, which was associated with upregulation of 
pulmonary Adrp transcripts and corresponding protein expression. 
Immunofluorescence double staining demonstrated markedly increased LIFs 
in interstitial compartments of distal alveolar walls in Nitrofen+ATRA, which 
was accompanied by an overall increase of lipid droplets in LIFs. A 
significantly enhanced radial alveolar count and decreased mean linear 
intercept was detected in nitrofen-exposed fetuses after prenatally 
administered ATRA. Relative mRNA expression of Lep and Lep-R was 
significantly upregulated in hypoplastic rat lungs following maternal ATRA
treatment. Light microscopy showed notably increased Lep and Lep-R
immunoreactivity in interstitial and alveolar epithelial cells of nitrofen-exposed 
fetuses that received ATRA application shortly before birth. 
Immunoflurescence revealed markedly increased alveolar SP-B protein 
expression in hypoplastic rat lungs after prenatal administration of ATRA. 
Conclusions: Disruption of the Thy-1/Adrp signaling cascade in hypoplastic 
rat lungs leads to a reduction of pulmonary LIFs with fewer lipid inclusions 
and impaired alveolar mesenchymal cell differentiation, which may contribute 
to decreased alveolar development and PH in the nitrofen-induced CDH 
model. Prenatal treatment with ATRA may therefore have a therapeutic 
potential in attenuating CDH-associated PH by increasing the expression of 
LIFs and thus Lep-mediated surfactant phospholipid synthesis, which in turn 
stimulate fetal alveolarization, distal airway maturation and de novo
surfactant production. 
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1 Introduction
Congenital diaphragmatic hernia (CDH) is characterized by a spectrum of 
developmental defects in the forming diaphragm, which are caused by 
disordered embryogenesis [Kluth et al., 1996a]. These malformations lead to 
an incomplete fusion of the diaphragmatic leaflets and subsequently to a 
hole in the diaphragm [Clugston and Greer, 2007]. As a consequence of this 
abnormal opening, the developing abdominal organs can protrude into the 
thoracic cavity, occupying space normally reserved to accommodate the 
growing lungs [Greer, 2013]. Because the process of CDH herniation occurs 
at the same time as bronchial subdivision and alveolarization, normal lung 
development is severely affected, resulting in pulmonary hypoplasia (PH) 
and persistent pulmonary hypertension of the newborn (PPHN) [Keijzer and 
Puri, 2010; Rottier and Tibboel, 2005]. Depending on the extent of this 
unfortunate combination, CDH patients often suffer from life-threatening 
respiratory distress at birth [Losty, 2014; Tovar, 2012]. Despite significant 
improvements in postnatal resuscitation and modern lung-protective 
strategies, CDH remains one of the major therapeutic challenges in modern 
neonatal intensive care, causing high mortality and long-term morbidity for 
survivors [Rocha et al., 2012; Peetsold et al., 2009].
Most of our current knowledge about the pathogenesis of CDH and 
the related morphological changes in hypoplastic lungs has originated from 
various experimental animal models [Chiu 2014; van Loenhout et al., 2009; 
Mortell et al., 2006]. Abnormal differentiation and malfunctioning of alveolar 
epithelial cells type II (AECII) have been demonstrated in the nitrofen-
induced CDH model, which contribute to the development of PH [Brandsma 
et al., 1994]. However, the exact molecular and cellular mechanisms causing 
impaired alveolarization and distal airway formation in hypoplastic lungs with 
CDH remain unknown. 
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Lipid-containing interstitial fibroblasts (LIFs) are critically important for 
fetal lung growth by stimulating differentiation of AECII and surfactant 
phospholipid production, which in turn increases alveolar maturation [Torday 
et al., 2003; McGowan and Torday, 1997]. Thymocyte antigen 1 (Thy-1) is a 
strongly expressed cell surface protein in LIFs, which plays a key role in 
alveolar lipid homeostasis by upregulating adipocyte differentiation-related 
protein (Adrp) [Varisco et al., 2012; McGowan and Torday 1997]. Adrp is 
necessary for the intracellular uptake of neutral lipids into LIFs and their 
subsequent transport to AECII [Schulz et al., 2002; Brasaemle et al., 1997].
Furthermore, LIFs express leptin (Lep), which binds to its receptor (Lep-R) 
on AECII, thus stimulating de novo synthesis and secretion of pulmonary 
surfactant proteins [Torday et al., 2002]. 
As Thy-1-/- knockout mice show a phenotype similar to PH in human 
CDH with impaired alveolar development and reduced proliferation of LIFs 
[Nicola et al., 2009], one objective of this study was to investigate the 
hypothesis that Thy-1 signaling is disrupted in hypoplastic rat lungs with 
toxicological induced CDH, which potentially may have an adverse effect on 
the expression and lipid content of pulmonary LIFs. In addition, as it has 
been demonstrated that retinoids (derivates of vitamin A) positively affect the 
proliferation of LIFs and expression of Lep and Lep-R in developing rat lungs 
[McGowan et al., 1995], another objective of this study was to investigate the 
hypothesis that prenatal in vivo administration of all-trans retinoic acid 
(ATRA) may have the potential to attenuate PH in this rodent CDH model by 
enhancing fetal alveolarization, which in turn may increase pulmonary LIF 
expression and thus surfactant production. The first indication that 
diaphragmatic defects may be associated with disruptions in retinoid 
signaling came from newborn rats with CDH whose mothers were bred on a 
vitamin A-deficient diet [Andersen, 1941]. Interestingly, the rate of CDH was 
found to be decreased when vitamin A was reintroduced into the maternal 
diet during midgestation [Wilson et al., 1953; Andersen, 1949]. 
Subsequently, similarities between retinoic acid receptor (RAR) double 
mutant mice and nitrofen-exposed fetal rats have suggested that nitrofen 
may interfere with the retinoid pathway [Mendelsohn et al., 1994]. 
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Further evidence for this theory was derived from the observation that 
the administration of vitamin A or ATRA to pregnant rats that had previously 
received nitrofen treatment showed a reduced incidence and severity of CDH 
in their offspring [Babiuk et al., 2004; Thebaud et al., 1999]. A series of in 
vivo and in vitro experiments have indicated that nitrofen may inhibit the 
activity of retinal dehydrogenase 2, a key enzyme necessary for the 
synthesis of ATRA that is expressed in the developing diaphragm and 
various other components of this important signaling pathway [Noble et al., 
2007; Chen et al., 2003; Mey et al., 2003]. In newborn infants, diaphragmatic 
defects have been associated with low retinol and retinol-binding protein 
levels, independent of their maternal retinol status [Beurskens et al., 2013; 
Beurskens et al., 2010; Major et al., 1998], supporting the idea that human 
CDH is linked with abnormal retinoid homeostasis. 
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2 Review of the literature
2.1 Historical overview 
The diaphragm and allied defects have been a source of fascination for 
scientists and clinicians for many centuries [Puri and Wester, 1997; Irish et 
al., 1996]. The ancient Greeks already recognized the diaphragm as a 
distinct anatomical structure in the human body. One of the earliest known 
literary references was by Homer in the 9th century BC, precisely describing 
wounds suffered by warriors during the Trojan War [Derenne et al., 1994]. At 
that time, however, the diaphragm was not tied to any particular physical 
function and was associated with the region of the body responsible for 
thought. The initial physiological explanations of respiration by Empedocles 
(490-430 BC) as well as the concepts introduced by Plato (428-348 BC) and 
Hippocrates (460-370 BC) did not include any significant participation of the 
diaphragm [Potter, 2010; Bury, 1929; Leonard, 1908]. Aristotle (384-322 BC) 
was the first to link respiration to a particular organ and a specific movement 
of the thorax, but in his theory the diaphragm was just a barrier separating 
the thorax from the abdomen and played no role in respiration [Peck, 1970]. 
Herophilus (335-280 BC) and his contemporary Erasistratus (304-250 BC), 
who systematically performed scientific dissections of human cadavers and 
animal experiments at the medical school in Alexandria, demonstrated for 
the first time that the diaphragmatic muscle fibers were the agents of 
respiratory movement [Von Staden, 1989]. Galen of Pergamon (129-200 AD) 
developed the concept of interaction between ribcage and abdominal 
muscles in maintaining the position of the diaphragm, showing a clear 
understanding of the principle that the diaphragm can move upward during 
an isovolume maneuver as long as the ribcage is allowed to expand 
[Derenne et al., 1995].  
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The term diaphragmatic hernia was introduced in 1575 by the French 
surgeon Ambroise Paré, who described two autopsy cases of traumatic 
diaphragmatic defects [Paré, 1575]. Following a post mortem examination of 
a 24-year-old man, the French physician Lazare Rivière discovered the first 
case of CDH, which he published in 1679 [Bonet, 1679]. In 1701, Sir Charles 
Holt reported the first pediatric case of CDH [Holt, 1701]. A detailed 
description of the gross anatomy and pathophysiology associated with CDH 
was presented in 1754 by the Scottish physician George Macaulay, who 
noted a right-sided defect in a newborn child that died 1.5 hours after birth 
due to severe breathing difficulties [Cullis and Davis, 2018; Macaulay, 1754].
The Italian anatomist Giovanni Battista Morgagni differentiated in his 
monograph from 1761 various subtypes of CDH, including the anterior defect 
that bears his name [Zani and Cozzi, 2008; Morgagni, 1761]. In 1819, the 
French physician René Laennec demonstrated that the diagnosis of CDH 
could easily be made by chest auscultation and also suggested that 
laparotomy might be the correct approach for hernia repair [Laennec, 1819]. 
Sir Astley Paston Cooper published in 1827 the first comprehensive report 
on classification, symptoms and pathology of CDH [Cooper, 1827]. The first 
cohort series of patients with CDH was collected by Henry Bowditch in 1847 
at the Massachusetts General Hospital in Boston, emphasizing the clinical 
criteria for diagnosis [Bowditch, 1853]. In 1848, the Czech anatomist Vincent 
Alexander Bochdalek accurately described a posterolateral defect in the 
diaphragm, which carries his name today [Bochdalek, 1848]. However, his 
understanding of the embryological pathogenesis of CDH was incorrect as
he speculated that the hernia resulted from an intrauterine rupture of the 
membrane in the lumbocostal triangle. The Swedish surgeon Gustaf 
Naumann proposed in 1888 a 2-cavity approach after unsuccessfully 
operating on a 19-year-old patient with an infarcted bowel that had herniated 
through a diaphragmatic defect [Naumann, 1888]. The first, but unsuccessful 
repair in a 3-year-old infant with CDH was published in 1889 by the American 
physician Joseph O’Dwyer, precisely describing a thoracic approach 
[O’Dwyer, 1889]. 
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The first successful CDH operation was performed in 1902 by the 
German surgeon Lothar Heidenhain, who corrected a diaphragmatic defect 
in a 9-year-old boy with a favorable 18-year follow-up [Aue, 1920; 
Heidenhain, 1905]. In a comprehensive review from 1925, the American 
surgeon Carl Hedblom showed that 75% of untreated cases with CDH died 
in the newborn period, suggesting that an earlier intervention might improve 
survival [Hedblom, 1925]. After that, Bettman and Hess presented in 1929 
the youngest patient with incarcerated CDH, who had successfully been 
operated on aged 3.5 months [Bettman and Hess, 1929]. Greenwald and 
Steiner reviewed symptoms of infants and children with CDH, concluding that 
this condition might not be as infrequent as it was generally believed 
[Greenwald and Steiner, 1929]. Surgical repair of CDH remained often 
unsuccessful until 1940, when Ladd and Gross reported 9 of 16 patients 
surviving surgery, the youngest being 40 hours old [Ladd and Gross, 1940]. 
Robert Gross subsequently performed in 1946 the first successful repair in a 
neonate with CDH less than 24 hours after birth [Gross, 1946]. In 1950, Koop 
and Johnson proposed a transthoracic approach as a means of closing the 
CDH under more direct vision [Koop and Johnson, 1952]. As the surgical 
expertise improved further, several innovative techniques [Holcomb Jr, 1962; 
Neville and Clowes Jr, 1954] were developed to address large diaphragmatic 
defects, including the use of pedicled abdominal muscle flaps [Simpson and 
Gassage, 1971; Rosenkrantz and Cotton, 1964], reverse latissimius dorsi 
flaps [Bianchi et al., 1983] and prosthetic patches [Geisler et al., 1977; 
Shaffer, 1964]. Extracorporeal membrane oxygenation (ECMO) was 
introduced in 1976 by Robert Bartlett and successfully applied in neonates 
with CDH for the management of respiratory insufficiency [German et al., 
1977; Bartlett et al., 1976]. In 1990, Michael Harrison and his team 
performed the first successful in utero repair in a 24 1/2-weeks-old male 
fetus with severe CDH using a Gore-Tex patch [Harrison et al., 1990].
22
Charles Stolar and co-workers presented in 1995 the concept of 
“gentle” ventilation in the management of CDH, characterized by 
preservation of spontaneous ventilation, permissive levels of hypercapnea 
and avoidance of high inspiratory airway pressures. This novel approach has 
subsequently reduced iatrogenic lung injury from barotrauma in CDH and 
resulted in improved survival with decreased need for ECMO (Wung et al., 
1995). The Dutch surgeons van der Zee and Bax reported in 1995 the first 
laparoscopic closure of a left-sided posterolateral CDH in a 6-month-old boy 
[van der Zee and Bax, 1995]. In order to stimulate the prenatal growth of 
hypoplastic lungs in fetuses with CDH, additional sophisticated strategies
were developed: placement of external metal clips on the fetal trachea by 
means of open hysterotomy [VanderWall et al., 1997; Harrison et al., 1996]
or fetoscopic neck dissection [Harrison et al., 1998] and internal tracheal 
occlusion with a detachable silicone balloon that was placed through a single 
uterine port using fetal bronchoscopy [Harrison et al., 2001]. A French team 
led by Francoise Becmeur published in 2001 the first thoracoscopic CDH
repair in three infants [Becmeur et al., 2001]. Although there is currently 
insufficient evidence to recommend fetal endoscopic tracheal occlusion
(FETO) as a part of routine clinical practice [Grivell et al., 2015], a few 
specialized fetal medicine centers in Europe, North and South America 
successfully perform this procedure [Persico et al., 2017; Belfort et al., 2017; 
Ruano et al., 2012; Dekoninck et al., 2011]. FETO has recently been 
reported to improve neonatal survival in CDH fetuses with severe PH 
compared with standard perinatal management, resulting in a survival rates
of 50% to 60% [Araujo Júnior et al., 2017; Al-Maary et al., 2016; Deprest et 
al., 2014a]. Further results from ongoing international randomized trials are 
anticipated in the near future [Deprest et al., 2014b].
Historically, a CDH that was diagnosed in the newborn period was almost 
uniformly fatal. The plethora of scientific discoveries and technical advances 
has contributed to the significant reduction in mortality of infant children with 
CDH.
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2.2 Congenital diaphragmatic hernia (CDH) 
2.2.1 Definition 
CDH is a prenatal defect in the integrity of the developing diaphragm that 
occurs during embryogenesis [Kluth et al., 1996b]. It is characterized by 
defective formation of the pleuroperitoneal membranes (PPMs) and/or 
incomplete fusion with the septum transversum (ST) [Clugston and Greer, 
2007]. In humans, closure of the pleuroperitoneal canal normally takes place 
around week eight of gestation by formation of a primordial diaphragm 
structure, which eventually separates the thoracic from the abdominal cavity 
prior to the major period of internal organ growth [Kluth et al., 1993].
However, in the instance of CDH, a significant proportion of the diaphragm is 
absent [Greer, 2013]. The resulting opening allows intrathoracic herniation of 
the abdominal viscera, causing mediastinal displacement to the contralateral 
side and thus severely compromises pulmonary development [Keijzer and 
Puri, 2010; Rottier and Tibboel, 2005].
2.2.2 Classification 
Traditionally, CDHs have been classified according to their presumed 
anatomical location and three different types of hernia can be distinguished 
[Pober, 2007]: 
Posterolateral (or Bochdalek) hernia 
This is the most common hernia type, comprising approximately 90-95% of 
all CDHs. About 80% are left-sided, 19% right-sided and 1% bilateral 
[Veenma et al., 2012; Clark et al., 1998]. Varying degrees of deficiency can 
be observed: an extremely large defect or complete absence of the hemi-
diaphragm including the posterior muscle rim is called diaphragmatic 
agenesis [Tsang et al., 1994; Bingham, 1959].
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Attempts of the CDH Study Group to more accurately categorize the severity 
of the defect has led to the introduction of a classification system that is 
based on intraoperative findings, comprising the anatomic spectrum from
small defects (A), which can be repaired primarily to total diaphragmatic 
agenesis (D) [Tsao and Lally, 2008]. 
Anterior retrosternal or parasternal (or Morgagni-Larry) hernia 
This hernia type is located in the most anterior portion of the diaphragm and 
results from a failure of the crural and sternal portions to fuse. It is usually 
accompanied by a hernia sac and comprises approximately 2% of all CDHs. 
Although some patients are asymptomatic with incidental discovery, acute or 
subacute pulmonary and gastrointestinal symptoms can indicate this 
diagnosis [Loong and Kocher, 2005]. 
Central (or septum transversum) hernia 
This is a very rare diaphragmatic defect, which primarily involves the non-
muscular or central tendinous portion of the diaphragm with presence of the 
entire muscular rim. 
Detailed examination of 181 autopsy records of children with congenital 
diaphragmatic defects at Boston Children's Hospital, however, has recently 
demonstrated wide phenotypic variations in size, shape, location and extent 
of organ displacement [Ackerman et al., 2012], suggesting that a clear 
distinction among the different subtypes of CDH can be problematic. 
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2.2.3 Epidemiology 
With an estimated incidence of 1 in 2,000 to 4,000 newborns, CDH is a 
relatively common birth defect that accounts for approximately 8% of all 
major congenital malformations [Stege et al., 2003; Skari et al., 2000; 
Langham Jr et al., 1996]. Recent population-based cohort studies from the 
USA [Shanmugam et al., 2017; Balayla and Abenhaim, 2014; Yang et al., 
2006; Dott et al., 1999; Torfs et al., 1992] and Western Australia [Colvin et 
al., 2005] have found prevalence rates ranging between 1.93 and 3.8 cases 
per 10,000 total births. Similar prevalence rates were reported by European 
registry-based studies, currently affecting between 2.3 and 2.7 cases per 
10,000 births [McGivern et al., 2015; Loane et al., 2011; Gallot et al., 2007].
However, the incidence of CDH in stillborns and therapeutic abortions seems 
to be less well documented. It can be estimated that roughly one third of all 
infants with CDH are stillborn, which is mainly a result of the associated fatal 
congenital anomalies [Stolar and Dillon, 2012] and adds a “hidden mortality” 
to the operative and postoperative deaths [Harrison et al., 1978]. A Swedish 
cohort study has observed an increasing number of terminations of CDH 
pregnancies of up to 23% [Burgos and Frenckner, 2017], which further 
supports the theory that the current mortality rate actually remained 
unchanged since the 1990s [Stege et al, 2003]. Overall, the true incidence of 
CDH is most likely considerably higher than seen in the neonatal surgical 
practice [Brownlee et al., 2009, Mah et al., 2009]. When stillborns are 
counted with live births, females appear to be more commonly affected than 
males [Stolar and Dillon 2012]. 
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2.3 Normal embryological development of the diaphragm
Due to the large number of complex spatiotemporal processes involving 
multiple cellular and tissue interactions, normal embryological development 
of the diaphragm remains incompletely understood [Merrell and Kardon, 
2013]. In humans, the diaphragm starts to develop at approximately four 
weeks of gestation, which is equivalent to embryonic day 12.5 in rats [Kluth 
et al., 1993]. Based merely on historic post mortem examinations of perinatal 
human specimens [Wells, 1954], it was believed over decades that the fully 
developed, dome-shaped, musculotendinous diaphragm is a composite 
structure that derives from the following four distinct embryonical
components: 
2.3.1 Septum transversum 
The anterior central tendon forms from an infolding of the ventrolateral body 
wall also known as ST, which is first seen as a thick mesodermal plate 
cranial to the pericardial cavity between the base of the thoracic cavity and 
the stalk of the yolk sac. The ST does not separate the thoracic and 
abdominal cavities entirely, but after the head folds ventrally around week 
four of gestation, it becomes a thick incomplete partition between the cavities 
with an opening on each side. Closure of these paired pericardioperitoneal 
canals normally occurs by week eight of gestation through fusion with the 
caudal PPMs and the primitive mediastinal mesenchyme ventral to the 
esophagus. Hereby, the right side usually closes before the left side [Moore 
et al., 2015; Wells, 1954]. 
2.3.2 Pleuroperitoneal membranes 
These membranes arise from an infolding of the posterolateral body wall.
Although they constitute large portions within the early fetal diaphragm, they 
represent only the relatively small dorsolateral portions of the fully developed 
structure. The PPMs merge with the dorsal mesentery of the esophagus and 
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with the dorsal part of the ST, which completes the partition between the 
thoracic and abdominal cavities and forms the primordial diaphragm [Moore 
et al., 2015; Wells, 1954]. 
2.3.3 Dorsal mesentery of the esophagus (or Mesoesophagus) 
The ST and the PPMs fuse with the dorsal mesentery of the esophagus and 
eventually form the median portion of the diaphragm. The crura of the 
diaphragm, a leg-like pair of diverging muscle bundles that cross in the 
median plane anterior to the aorta, evolve from myoblasts that grow into the 
dorsal esophageal mesentery [Moore et al., 2015; Wells, 1954].  
2.3.4 Muscular ingrowth from the lateral body walls 
Between gestational week 9 and 12, the lungs and pleural cavities enlarge 
significantly, thus invading into the lateral body walls. During this process,
the body wall tissue splits into an internal layer that contributes to the 
peripheral parts of the diaphragm and subsequently forms its muscular 
portion [Moore et al., 2015; Wells, 1954].  
The advent of labeling techniques for developmentally regulated molecules 
and the use of transgenic mouse models has made it possible to 
systematically elucidate multiple stages of diaphragm myogenesis during 
normal diaphragmatic development and in CDH models [Greer, 2013; Babiuk 
et al., 2003; Greer et al., 1999]. Hereby, the mesenchymal-derived 
pleuroperitoneal fold (PPF) has recently been identified as a key structure 
[Sefton et al., 2018; Merrell et al., 2015; Clugston et al., 2010a; Greer et al., 
2000; Allan and Greer, 1997]. However, it remains controversial if the muscle 
precursor cells and phrenic axons, which originate from the PPF, form the 
diaphragm alone or how much the posthepatic mesenchymal plate 
contributes to the closure of the pleuroperitoneal canal [Mayer et al., 2011; 
Babiuk and Greer, 2002]. 
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2.4 Normal prenatal development of the lung 
Although starting from different pathways and anlages, diaphragm and lung 
morphogenesis are interrelated [Kays, 2006]. In humans, normal airway 
formation begins around week four of gestation with outgrowth of two small 
buds of endodermally derived foregut cells and can be divided into five 
overlapping stages: embryonic, pseudoglandular, canalicular, saccular and 
alveolar [Smith et al., 2010; Rottier and Tibboel, 2005]. During these 
individual phases, which each involve coordinated growth and differentiation 
of the epithelial and mesenchymal components of the immature lung, the 
pulmonary system develops by dichotomous branching from two primitive 
endodermal buds to a functional organ with a large surface area and highly 
differentiated alveoli [Morrisey and Hogan, 2010]: 
2.4.1 Embryonic stage 
This is the stage of actual organogenesis. The embryonic lung and trachea 
originate from the caudal end of the laryngotracheal diverticulum by 
formation of an initial respiratory bud, which divides in humans at the end of 
the fourth week into two outpouchings [Burri, 1984]. These primary bronchial 
buds enlarge early in week five to form a primordial main bronchus and by 
the end of the sixth week they have grown laterally into the 
pericardioperitoneal canals as defined lobar and segmental portions of the 
airway tree [Burri, 1984]. At seven weeks, subsegmental branching is 
evident, which is driven by signals from the surrounding mesenchyme 
[Alescio and Cassini, 1962]. 
2.4.2 Pseudoglandular stage 
During this stage, cellular airway differentiation begins in a proximodistal 
pattern [Merkus et al., 1996]. Epithelial tubes lined with cuboidal epithelial 
cells undergo peripheral branching and lengthening, thus resembling an 
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exocrine gland with marked widening of distal airspaces at the expense of 
intervening mesenchyme. By 16 weeks, the branching morphogenesis is 
completed and 20 generations of conducting airways are laid down [Kitaoka 
H et al., 1996]. However, this fluid-filled primitive respiratory tree structure is 
too immature to support efficient gas exchange. 
2.4.3 Canalicular stage 
This period partially overlaps the pseudoglandular stage because cranial 
parts of the lung mature faster than caudal ones. Bronchi and terminal 
bronchioles further expand in diameter and length, which is accompanied by 
vascularization along the airways and multiplication of capillaries [deMello et 
al., 1997]. At 24 weeks, each terminal bronchiole has given rise to two or 
more respiratory bronchioles, each of which has divided into three to six 
crude alveolar air sacs [Burri, 1984]. Histologically, airway epithelial cells are 
differentiated into peripheral squamous cells and proximal cuboidal cells. 
2.4.4 Saccular stage 
During this period, many more alveolar sacs develop with substantial 
thinning of the interstitium during the terminal saccular stage. This results 
from apoptosis as well as ongoing differentiation of mesenchymal cells 
[Hashimoto et al., 2002]. In addition, the capillary network proliferates rapidly 
and begins to sprout into the mesenchyme around these sacs. By 26 weeks, 
the terminal sacs are mainly lined with differentiated squamous epithelial 
cells, called type 1 pneumocytes [Mercurio and Rhodin, 1976], and scattered 
precursors of AECII [Otto-Verberne et al., 1988], which ultimately become 
responsible for surfactant production. 
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2.4.5 Alveolar stage 
At the beginning of the alveolar stage, each respiratory bronchiole terminates 
in a cluster of thin-walled alveolar sacs, separated from one another by loose 
connective tissue. Sacs analogous to primordial alveoli appear at 32 weeks 
and represent future alveolar ducts [Burri, 1984]. The epithelial lining of these 
sacs attenuates to a thin squamous epithelial layer and type I pneumocytes 
become so thin that the adjacent capillaries bulge into the alveolar airspaces. 
By the late fetal period, true alveoli are present and the lung is capable of 
respiration because the alveolocapillary membrane is thin enough to allow 
sufficient gas exchange with mature AECII secreting pulmonary surfactant 
[Merkus et al., 1996]. 
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2.5 Pathogenetical and -physiological aspects of CDH
The etiology of the diaphragmatic defect is identified in less than 50% of 
patients with CDH, although numerous chromosomal aberrations and gene 
mutations have been linked to this congenital malformation [Slavotinek, 
2014; Longoni et al., 2014; Wynn et al., 2014]. From a surgical perspective, it 
is relatively easy to repair the defect in the diaphragm either by primary 
closure or reconstruction using a patch, but the main problem remains the 
associated disturbed lung development, resulting in severe PH and PPHN
[Ameis et al., 2017; Harting, 2017]. Both conditions occur to a variable extent 
in patients with CDH and due to the absence of sufficient lung-protective 
strategies, most of the newer treatment modalities such as exogenous 
surfactant, inhaled nitric oxide, high-frequency oscillation and ECMO have 
replaced high mortality rates with significant long-term morbidity in survivors, 
including bronchopulmonary dysplasia, chronic lung disease, 
gastroesophageal reflux, scoliosis and various neurodevelopmental deficits 
[Puligandla et al., 2015; Kotecha et al., 2012; van den Hout et al., 2011; 
Antonoff et al., 2011; Tsao and Lally, 2008]. Prenatally diagnosed CDH is 
often associated with larger defect sizes compared to those with a postnatal 
diagnosis, and consequently have higher morbidity and mortality [Burgos et 
al., 2018]. Moreover, a significant hidden mortality exists in CDH due to 
termination of pregnancy and intrauterine fetal demise, with an overall 
mortality rate of 45% in a recent population-based study from Sweden 
[Burgos and Frenckner, 2017]. Therefore, CDH represents one of the major 
therapeutic challenges not only in modern neonatal intensive care units, but 
also for other specialties involved [Danzer and Hedrick, 2014; Tovar, 2012]. 
In the past, it has been assumed that the different parts of the 
diaphragm fail to fuse properly [Broman, 1901]. Consequently, the 
pleuroperitoneal canal does not close and PH was believed to be the result 
of mechanical compression by herniation of abdominal viscera into the 
thoracic cavity [Wells, 1954]. It has also been suggested that a primary 
disturbance of the pulmonary development might negatively influence the 
formation of the fetal diaphragm, thereby causing CDH [Iritani, 1984].
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However, it has been demonstrated by combining teratogenic and transgenic 
animal models that these hypotheses are not true [Guilbert et al., 2000].
Moreover, Fgf10 knockout mice do not have any lungs but show 
normal diaphragmatic development [Sekine et al., 1999]. The so-called “dual-
hit hypothesis” implicates a primary disruption in bilateral lung development 
before closure of the diaphragm combined with a second ipsilateral insult 
caused by intrathoracic herniation and thus interference with fetal breathing 
movements [Keijzer et al., 2000; Jesudason et al., 2000]. Recently, a 
proliferative abnormality of the PPF has been postulated for the insufficient 
formation of the diaphragm [Clugston et al., 2010a; Greer et al., 2000; Allan 
and Greer, 1997]. Surprisingly, the origin of the diaphragmatic defect 
appears to lie in the mesenchymal component of the PPF, supporting the 
hypothesis that CDH occurs independently of myogenesis and lung 
formation [Babiuk RP 2002]. Likewise, Gata4 mosaic mutations in PPF-
derived muscle connective tissue fibroblasts result in the development of 
localized amuscular regions that are biomechanically weaker and more 
compliant, leading to CDH [Merrell et al., 2015]. Also, the recruitment of 
muscle progenitors from cervical somites to the nascent PPFs is uniquely 
mammalian and a key developmental innovation essential for the evolution of 
the muscularized diaphragm [Sefton et al., 2018]. Regardless of all these 
theories, the exact pathogenesis of CDH and associated pulmonary
malformation remains unclear. 
Hypoplastic lungs in CDH are characterized by immaturity and smaller 
size with a significantly decreased number of terminal airway generations, 
thickened alveolar walls, increased interstitial tissue, diminished alveolar 
airspaces and reduced gas-exchange surface area [Sabharwal et al., 2000; 
Brandsma et al., 1994]. In addition, abnormal differentiation and 
malfunctioning of AECII have been reported in a rat model of CDH-
associated PH, which in turn leads to surfactant deficiency [Brandsma et al., 
1994]. Yet, controversy remains whether surfactant synthesis and maturation 
are also disrupted in human neonates with CDH [Janssen et al., 2009; 
Boucherat et al., 2007; Janssen et al., 2003]. Nevertheless, data from the 
CDH Study Group has suggested that surfactant replacement for newborns
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with diaphragmatic defects does not actually provide significant outcome 
benefits in respect to survival rate, length of ECMO course, length of 
intubation, or subsequent need for supplemental oxygen [Colby et al., 2004; 
Van Meurs, 2004; Lally et al., 2004].  
Apart from the gas-exchange layer, well-documented changes are 
present in the vascular components consisting of arterial media hyperplasia, 
peripheral muscularization of smaller pre-acinar vessels and adventitial 
thickening [Sluiter et al., 2011; Taira et al., 1998; Yamataka and Puri, 1997]. 
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2.6 Animal models of CDH
Most of our current knowledge about the structural and morphological 
changes in hypoplastic lungs associated with CDH has originated from 
experimental animal models, in which the diaphragmatic defect is either 
surgically, transgenically or toxicologically created [Chiu, 2014; van Loenhout 
et al., 2009; Clugston et al., 2006; Mortell et al., 2006]. 
2.6.1 Surgical models 
Surgically created diaphragmatic defects in fetal lambs and rabbits are useful 
for investigating interventional treatment strategies such as in utero repair 
and tracheal occlusion [Jelin et al., 2011; Lipsett et al., 2000; De Paepe et 
al., 1999; Hedrick et al., 1994], but are less helpful in studying the earlier 
pathogenesis of PH in CDH as well as being more expensive and time-
consuming compared to rodent models. 
2.6.2 Genetic models 
Over the last two decades, several knockout models for genes involved in 
embryonic mouse development, such as for Wt1 [Moore et al., 1998; 
Kreidberg et al., 1993], Shh [Pepicelli et al., 1998], Gli2/Gli3 [Motoyama et 
al., 1998], Slit3 [Liu et al., 2003; Yuan et al., 2003], Fog2 [Ackerman et al., 
2005], Gata4/Gata6 [Merrell et al., 2015; Jay et al., 2007; Molkentin, 2000], 
Coup-TFII [You et al., 2005], Pdgfrα [Bleyl et al., 2007], Kif7 [Coles and 
Ackerman, 2013], Lox [Hornstra et al., 2003; Mäki et al., 2002], RARs 
[Mendelsohn et al., 1994], Robo1 [Xian et al., 2001] and Sox7 [Wat et al., 
2012] have been established, which show various phenotypes of CDH and
disruption in lung branching morphogenesis. However, until now only the 
Fog2 gene mutation has been identified in a patient with non-syndromic CDH 
[Bleyl et al., 2007]. 
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2.6.3 Nitrofen model 
Administration of the herbicide nitrofen (2,4-dichlorophenyl-p-nitrophenyl 
ether) to pregnant rodents has been found to cause different developmental 
anomalies in heart, lung and diaphragm [Ambrose et al., 1971]. Maternal 
exposure during midgestation results in CDH in approximately 70% and PH 
in 100% of the offspring [Noble et al., 2007]. Therefore, the toxicologically 
introduced nitrofen model has widely been used to investigate the CDH-
associated anomalies, as the timing of the diaphragmatic insult and bilateral 
PH are remarkably similar to the human situation [van Loenhout et al., 2009; 
Beurskens et al., 2007]. Nevertheless, the significance of these potential 
teratogenic effects has never been proven in humans so far. 
Although none of the available animal models for CDH are perfect in 
mimicking the human diaphragmatic defect, they all have provided new 
insights into the underlying pathogenesis and associated pathophysiological 
alterations in pulmonary development. 
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2.7 Involvement of all-trans retinoic acid (ATRA) and 
retinoid signaling during fetal lung development 
ATRA, one of the most biologically active metabolites of vitamin A, is an 
essential component of the complex gene network that regulates growth of 
several organ systems, including lung morphogenesis and formation of the 
diaphragm [Ross et al., 2000]. During fetal lung development, retinoids are 
crucial in each of the developmental stages [Montedonico et al., 2008b].
ATRA is known to be critically involved in the saccular phase through 
stimulation of AECII proliferation [Nabeyrat et al., 1998]. A previous research 
study has reported a 50% increase in the number of pulmonary alveoli in 
newborn rats after treatment with ATRA, suggesting an important role of 
retinoids during alveolarization [Massaro and Massaro, 1996]. Recent 
findings from animal experiments have revealed that disruption of retinoid 
signaling contributes to the formation of CDH and associated lung hypoplasia 
[Clugston et al., 2010b; Greer et al., 2003]. Furthermore, it has been 
demonstrated that prenatal administration of ATRA during late gestation 
upregulates pulmonary expression of several genes involved in the retinoid 
signaling pathway [Doi et al., 2009]. It has also been shown that ATRA 
reduces the severity of PH in nitrofen-induced hypoplastic lung explants 
[Montedonico et al., 2006] and rescues PH in calorie-restricted developing 
rat lungs [Londhe et al., 2013]. Additional evidence that prenatal 
administration of ATRA stimulates alveolarization in hypoplastic lungs has 
been provided by in vivo studies in rats with nitrofen-induced CDH
[Montedonico et al., 2008a], indicating that ATRA may have a therapeutic 
potential in attenuating CDH-associated PH. However, further research is 
needed to establish the exact molecular and cellular effects of ATRA 
treatment on fetal alveolar development. 
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2.8 Lipid-containing interstitial fibroblasts (LIFs) and their 
role in fetal lung development 
LIFs, also known as lipofibroblasts, because of their characteristic lipid 
inclusions, play an essential role in fetal lung development by inducing 
alveolar epithelial cell proliferation, growth and differentiation [McGowan and 
Torday, 1997]. Pulmonary LIFs, which are mainly expressed in the alveolar 
interstitium in close contact to AECII, have been shown to actively absorb, 
store and transport neutral lipids [McGowan and Torday, 1997]. Due to this 
capability, they are not only critically involved in the regulation of alveolar 
lipid homeostasis and differentiation of adjacent AECII, but also in the de
novo production of surfactant phospholipids by supplying one of the key 
components for their synthesis [Torday et al., 2003; McGowan and Torday, 
1997; Nunez and Torday, 1995]. Moreover, it has been revealed that 
proliferation of AECII and associated formation of alveoli depends on the 
amount of ATRA in LIFs [Dirami et al., 2004; Okabe et al., 1984]. In rodents, 
LIFs are first evident during the late canalicular stage of lung development 
with a significant increase over the last few days of gestation [Torday et al., 
1995; Tordet et al., 1981]. Thy-1 is a highly expressed cell surface protein in 
this specific subset of pulmonary fibroblasts, which are important for fetal 
alveolarization and alveolar maturation [Varisco et al., 2012]. The expression 
of Thy-1 has been found to increase continuously during the neonatal period, 
coinciding with the onset of alveolar formation [Varisco et al., 2012]. 
Interestingly, Thy-1-/- mice exhibit impaired alveolar development and 
reduced proliferation of pulmonary LIFs, which results in a PH-similar 
phenotype [Nicola et al., 2009]. It has also been reported that Thy-1 has the 
ability to enhance the lipid content of LIFs by upregulation of Adrp [McGowan 
and Torday, 1997]. Adrp is in turn necessary for the alveolar lipid 
homeostasis and associated pulmonary surfactant production by mediating 
the intracellular uptake of neutral lipids into LIFs and their subsequent 
transport to AECII [Schultz et al., 2002]. This functional lipogenic molecular 
marker, which clearly characterizes pulmonary LIFs, shows a significant 
increase in expression immediately before birth [Brasaemle et al., 1997]. 
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The paracrine stimulation of alveolar epithelial cell maturation also 
requires the expression of Lep by LIFs, a 16 kDa peptide product of the ob 
gene and its corresponding receptor Lep-R on AECII [Torday JS 2002]. Lep 
and Lep-R are strongly expressed by these two types of distal alveolar cells 
during the saccular stage of fetal lung development with a 7- to 10-fold 
increase prior to term [Henson et al., 2004; Torday et al., 2002]. Lep-deficient 
mice showed decreased alveolarization with reduced pulmonary surfactant 
phospholipid synthesis [Tankersley et al., 1996], similar to human and 
nitrofen-induced PH. Figure 1 displayes a schematic diagram of the relevant 
components in this signaling pathway. In addition, it has been demonstrated 
that Lep and Lep-R expression in developing lungs is regulated by retinoid 
signaling [McGowan et al., 1995], suggesting a therapeutic potential of ATRA 
in attenuating CDH-associated PH by stimulating alveolar maturation through 
an increased expression of pulmonary LIFs and thus proliferation of AECII. 
 
 
Figure 1  Schematic diagram summarizing how Thy-1 increases the lipid content of alveolar LIFs 
by upregulation of the lipogenic marker Adrp, which in turn stimulates the intracellular uptake of 
neutral lipids into LIFs. Lep and Lep-R then mediate the transport of these lipid droplets to AECII, 
which is necessary for phospholipid synthesis and subsequent pulmonary surfactant production. 
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3 Aims and objectives of the study 
The overall aim of this dissertation was to investigate the underlying 
molecular and cellular effects of prenatally administered ATRA in alveolar 
LIFs and AECII and its impact on fetal lung development and surfactant 
synthesis in the nitrofen-induced rat model of CDH. Based on previous 
studies [Montedonico et al., 2008a; Montedonico et al., 2006], it can be 
assumed that ATRA may have the ability to enhance alveolarization in fetal 
rats with experimentally induced diaphragmatic defects by increasing 
pulmonary LIFs and thus to attenuate CDH-associated PH. In order to prove 
this hypothesis, in vivo treatment studies with maternal application of ATRA 
shortly before birth were performed and effects on fetal alveolar maturation 
were assessed by using molecular genetic, immunohistochemical/-
fluorescence and stereo-/morphometric analysis techniques. 
The specific objectives of this work were: 
1. To identify potential disruptions of Thy-1 signaling in hypoplastic rat 
lungs with nitrofen-induced CDH, which may have an adverse effect 
on the lipid content of pulmonary LIFs and thus form the basis for a
therapeutic approach with ATRA at the end of gestation. 
2. To analyze the pulmonary Adrp expression levels in control- and 
nitrofen-exposed fetuses, which may be accompanied by an overall
reduction of LIFs in hypoplastic rat lungs with diaphragmatic defects 
that can potentially be reversed by ATRA. 
3. To evaluate the impact of prenatal ATRA application on the 
expression of pulmonary LIFs in hypoplastic rat lungs with nitrofen-
induced CDH, which in turn may stimulate fetal alveolarization in PH. 
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4. To examine if prenatally administered ATRA has the ability to 
upregulate leptin signaling in nitrofen-exposed rat fetuses with 
diaphragmatic defects, which may result in a significant increase of de
novo surfactant production. 
As CDH continues to be a relatively complex and rare birth defect with often 
unpredictable outcome, there is urgent need to foster further research 
activities in this field. An appreciation of CDH literature and scientific 
progress is therefore essential for both clinicians and basic scientists to plan 
future research projects. Until now, no detailed study has systematically 
analyzed the immense number of publications relating to CDH research and 
the true extent of the scientific output in this area remains unclear. 
Hence, an additional objective of this work was: 
5. To assess the global CDH research activity using a combination of 
validated scientometric methods and noval visualization techniques, 
which may help to establish future collaborations and thus to advance 
patient care. 
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4 Material and methods 
4.1 Animal model, drugs and experimental design (I-IV) 
4.1.1 Animal protocol and observational studies (I-IV) 
Pathogen-free Sprague-Dawley® rats (Harlan Laboratories, Shardlow, UK) 
were kept in a well-controlled environment (50-55% humidity, 19-21°C, 12-h
light period, food and water ad libitum). Following acclimatization, animals 
were mated overnight and females were checked daily for the presence of 
spermatozoids in the vaginal smear. The day of plugging was defined as 
embryonic day 0.5 (E0.5) and timed-pregnant subjects were randomly 
divided into two experimental groups (“Nitrofen” and “Control”). On E9.5, 
dams were briefly anesthetized with 2% volatile isoflurane (Piramal 
Healthcare Ltd, Morpeth, UK) and 100 mg nitrofen (2,4-dichlorophenyl-p-
nitrophenyl ether) (Wako Chemicals GmbH, Neuss, Germany) was 
administered in 1 ml olive oil via oral-gastric lavage, whereas control animals 
received vehicle alone.  
For all following studies (irrespective of the experimental design), fetuses 
were delivered via caesarean section under anesthesia and sacrificed by 
decapitation on the selected end point E21.5 (alveolar phase). After 
laparotomy, diaphragms were inspected under a Leica S8AP0 
stereomicroscope (Leica Microsystems AG, Heerbrugg, Switzerland) for 
diaphragmatic defects and whole lungs were microdissected via thoracotomy 
under sterile conditions. Specimens for stereo-/morphometric, lipid and 
immunohistochemical/-fluorescence analysis were fixed in 4% 
paraformaldehyde (PFA) (Santa Cruz Biotechnology Inc, Santa Cruz, USA) 
diluted in phosphate buffered saline (PBS) (Oxide Ltd, Basingstoke, UK) for 
24 hrs, whereas specimens for RNA isolation and subsequent quantitative 
real-time polymerase chain reaction (qRT-PCR) were snap-frozen in liquid 
nitrogen (and stored at -80°C) until further processing was carried out. 
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In order to obtain a representative number of samples for the 
observational studies, fetal lungs in each experimental group originated from 
at least four different dams (6-8/litter). Hence, a total of 56 specimens were 
used, which can be divided into Controls (n = 28) and nitrofen-induced CDH-
associated PH (n = 28).
4.1.2 In vivo treatment studies with ATRA (III, IV)
On E18.5, control and nitrofen-treated rats were randomly assigned to one of 
the four treatment groups: Control+Placebo, Control+ATRA,
Nitrofen+Placebo and Nitrofen+ATRA. Based on previous studies, 5 mg/kg 
ATRA (Sigma Aldrich, Saint Louis, USA) was dissolved in 1 ml cottonseed oil 
and injected intraperitoneally under short anesthesia once daily on E18.5, 
E19.5 and E20.5 [Montedonico et al., 2008] to achieve sufficient tissue levels 
in the fetuses without exposing them to toxicological dosages [Morriss-Key, 
1999; Chen et al., 1995], whereas control animals received dissolvent alone.
Dams were anesthetized on E21.5 and body weight of delivered fetuses was 
measured before their whole lungs were dissected (Figure 2). Moreover, all 
specimens were weighed before further processing was accomplished.
Figure 2 Experimental design for in vivo treatment studies with ATRA and Placebo. 
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Fetuses for the in vivo treatment studies originated from at least six different 
dams (4-6/litter). In total, 128 fetal lung samples were used, which can be 
divided into Control+Placebo (n = 32), Control+ATRA (n = 32), 
Nitrofen+Placebo (n = 32) and Nitrofen+ATRA (n = 32). 
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4.2 Preparation of fetal lung specimens for stereo-/ 
morphometric, lipid and immunohistochemical/-
fluorescence analysis (I-IV) 
The PFA-fixed lung specimens were washed overnight in ice-cold PBS to 
remove exterior debris, embedded in O.C.T. compound mounting medium 
(VWR International Ltd, Dublin, Ireland) and snap-frozen in liquid nitrogen.
Frozen blocks were stored at -80°C until cryosectioning was performed. All 
lung specimens were cut transversely at a thickness of 10 μm using a 
CM1900 cryostat (Leica Microsystems GmbH, Nussloch, Germany) at -20°C 
and serial sections were mounted on SuperFrost® Plus microscopy glass 
slides (VWR International Ltd, Dublin, Ireland).  
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4.3 Molecular genetic analysis (I-IV) 
4.3.1 Total RNA isolation (I-IV) 
After thawing and homogenization, total RNA was extracted from snap-
frozen lung specimens with the acid guanidinium thiocyanate-phenol-
chloroform extraction method using a TRIzol® reagent (Invitrogen™ by Life 
Technologies™, Carlsbad, USA) according to the manufacturer’s protocol. 
Concentration and purity of total RNA was determined with a NanoDrop ND-
1000 UV-vis® spectrophotometer system (Thermo Scientific Fisher, 
Wilmington, USA). 
4.3.2 Complementary DNA synthesis (I-IV) 
Reverse transcription of 1 μg total RNA was carried out with a LightCyler®
480 Instrument (Roche Diagnostics GmbH, Mannheim, Germany) at 85°C for 
3 min (denaturation), at 44°C for 60 min (annealing), and at 92°C for 10 min 
(reverse transcriptase inactivation) using a Transcriptor High Fidelity cDNA 
Synthesis Kit® (Roche Diagnostics GmbH, Mannheim, Germany) according 
to the manufacturer’s protocol. The resulting complementary DNA was then 
used for qRT-PCR. 
4.3.3 Quantitative real-time polymerase chain reaction (I-IV) 
Pulmonary gene expression of Thy1, Adrp, Lep and Lep-R was quantified 
with a LightCyler® 480 System (Roche Diagnostics GmbH, Mannheim, 
Germany) using a LightCyler® 480 SYBR® Green I Master Mix (Roche 
Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s 
protocol. Primer sequences for target and reference genes were designed 
with the online tool Primer3 (http://primer3.ut.ee) using rat nucleotide 
sequences from the open access GenBank® database 
(http://www.ncbi.nlm.nih.gov/genbank). A genomic service provider (Eurofins 
MWG Operon, Ebersberg, Germany) synthesized all selected primers. 
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Gene-specific primer sequences are listed in Table 1. After an 
initialization phase at 95°C for 5 min, 55 amplification cycles were carried 
out. Each cycle included an initial denaturation step at 95°C for 10 sec, an
annealing step at 60°C for 15 sec and an elongation step at 72°C for 10 sec. 
The final elongate temperature was 65°C for 1 min. Relative mRNA 
expression levels were determined using the comparative cycle threshold 
method and results were normalized to the expression of our housekeeping 
gene β-actin. All qRT-PCR experiments were run in duplicate for each 
sample and primer pair. 
Table 1  Gene-specific primer sequences for quantitative real-time polymerase chain reaction. 
Gene Sequence (5’-3’) Product size (bp)
Thy-1
Forward
Reverse
Adrp
Forward
Reverse
Lep
Forward
Reverse
Lep-R
Forward
Reverse
β-actin
Forward
Reverse
TTG CCT TCT AAG CCA GAT GC
AGC AGC GCT CTC CTA TCT TG
CTC TCG GCA GGA TCA AAG AC
CGT AGC CGA CGA TTC TCT TC
ATG GGA CAG CCA AAC AAA AG
TCC TGA GCC ATC CAG TCT CT
TGA CAC CAA AAC CCT CAT CA
ATG AAG TCC AAA CCG GTG AC
TTG CTG ACA GGA TGC AGA AG
TAG AGC CAC CAA TCC ACA CA
174
171
168
181
108
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4.4 Oil red O staining (I-III) 
Lipid content in pulmonary tissue was assessed by staining with oil red O 
(ORO). Thawed, frozen sections were immersed in 100% propylene glycol 
(Sigma Aldrich, Saint Louis, USA) for 5 min before ORO staining was 
performed. The ORO solution was prepared by slowly dissolving 0.7 g ORO 
powder (Sigma Aldrich, Saint Louis, USA) in 100 ml propylene glycol, while 
heating to 100°C for a few minutes. The resulting solution was filtered twice 
and cooled down before further use. Sections were immersed in ORO 
solution for 7 min, followed by 3 min in 85% propylene glycol. After 
counterstaining with hematoxylin for 30 sec, sections were coverslipped 
using Mowiol® (Sigma Aldrich, Saint Louis, USA) and independently 
evaluated by two investigators who were unaware of the respective 
experimental group. 
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4.5 Immunohistochemistry (I-IV) 
4.5.1 Immunohistochemical staining (I-IV) 
Localization of alveolar LIFs was ascertained by labeling for Adrp, a 
functional lipogenic marker protein characterizing this specific subset of lung 
fibroblasts and downstream target of Thy-1. The distribution of alveolar Lep 
and Lep-R proteins was evaluated by specific immunohistochemical staining 
in order to localize their exact cellular expression. Thawed frozen sections 
were incubated with PBS containing 1.0% Triton X-100 (Sigma Aldrich, Saint 
Louis, USA) for 20 min to improve cell permeabilization. In order to avoid 
masking of antigenic sites, sections were immersed in heated Target 
Retrieval Solution® (DAKO Ltd, Cambridgeshire, UK) in a microwave oven at 
750 W for 15 min. Endogenous peroxidase activity was blocked using 
Peroxidase Block® (DAKO Ltd, Cambridgeshire, UK) according to the 
manufacturer’s protocol for 5 min. To prevent nonspecific absorption, 
sections were blocked with 10% normal goat serum (Sigma Aldrich, Saint 
Louis, USA) for 30 min, followed by incubation with affinity-purified rabbit 
polyclonal anti-Adrp (sc-32888, 1:50) (Santa Cruz Biotechnology Inc, Santa 
Cruz, USA), anti-Lep (ab3583, 1:100) and anti-Lep-R (ab5593, 1:250) 
antibodies (Abcam plc, Cambridge, UK) at 4°C overnight. On the next day, 
sections were washed in PBS + 0.05% Tween and incubated with 
horseradish peroxidase-conjugated anti-rabbit secondary antibodies (K4011, 
1:100) (DAKO Ltd, Cambridgeshire, UK) at room temperature for 30 min. 
The antibody-antigen complexes were then visualized by staining with 
diaminobenzidine (DAB) + Substrate Buffer® and DAB + Chromogen®
(DAKO Ltd, Cambridgeshire, UK) for 30 sec. After counterstaining with 
hematoxylin (Sigma Aldrich, Saint Louis, USA) for 10 sec, sections were 
coverslipped using DPX Mountant for histology (Sigma Aldrich, Saint Louis, 
USA). All sections were independently evaluated by two investigators who 
were unaware of the respective experimental group with a Leica DM LB 
research microscope (Leica Microsystems GmbH, Wetzlar, Germany) using 
the image and data management software Leica IM50, version 1.20 (Leica 
Microsystems AG, Heerbrugg, Switzerland). 
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4.5.2 Immunofluorescence double staining (I-III)
The distribution of pulmonary LIFs was evaluated by immunofluorescence 
double staining for alpha smooth muscle actin (αSMA), which is known to be 
absent in this specific subset of lung fibroblasts, and lipid droplets. In order to 
localize Thy-1 expression and to determine lipid content in alveolar LIFs,
immunoflurescence double staining with specific Thy-1 antibodies and ORO 
was performed. Thawed frozen sections were blocked with 10% normal goat 
serum for 30 min, followed by incubation with either affinity-purified mouse 
anti-αSMA (M0851, 1:500) (DAKO Ltd, Cambridgeshire, UK) or anti-Thy-1
(ab225, 1:100) (Abcam plc, Cambridge, UK) antibodies and ORO solution at 
4°C overnight. On the next day, sections were washed in PBS + 0.05% 
Tween and incubated with Alexa Fluor® 488 goat anti-mouse secondary 
antibodies (A11029, 1:100) (Bio-Sciences Ltd, Dun Laoghaire, Ireland) for 30 
min. The sections were counterstained with DAPI (10236276001, 1:1000) 
(Roche Diagnostics GmbH, Mannheim, Germany) for 10 min to visualize 
double-stranded DNA. Following coverslipping with fluorescent mounting 
medium (DAKO Ltd, Cambridgeshire, UK), two investigators unaware of the 
respective experimental group independently evaluated all sections with a 
LSM 700 confocal laser scanning microscope (Carl Zeiss MicroImaging 
GmbH, Jena, Germany). The acquired images were meticulously analyzed 
using the image processing and analysis software program ZEN (Carl Zeiss 
MicroImaging GmbH, Jena, Germany). 
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4.6 Assessment of fetal lung stereo-/morphometry (IV) 
Two independent-blind investigators unaware of the experimental group 
performed fetal lung stereo-/morphometry, which was objectively assessed 
by determining radial alveolar count (RAC) and mean linear intercept (MLI) 
on hematoxylin- and eosin-stained (Sigma Aldrich, Saint Louis, USA) 
sections. Fifty randomly selected, non-overlapping fields from serial sections 
were investigated under a Leica DM LB research microscope (Leica 
Microsystems GmbH, Wetzlar, Germany). Each field was viewed at 40-fold 
magnification, and the image was digitized and projected on a computer 
screen using a Leica DC300F digital camera (Leica Microsystems AG, 
Heerbrugg, Switzerland). For each field, the number of alveoli was counted 
visually and RAC was performed by identifying respiratory bronchioles, as 
previously described [Randell et al., 1989]. Briefly, the number of distal air 
sacs that were transacted by a line drawn from a terminal respiratory 
bronchiole to the nearest pleural surface was counted. No counts were made 
if the respiratory bronchiole was nearer to the edge of the slide than to the 
nearest connective tissue septum. The MLI represents the average alveolar 
diameter, alveolar septal thickness (AST) and tissue density, which is the 
proportion of the field occupied by tissue (area occupied by tissue/area 
occupied by lung tissue + alveoli). All images were independently analyzed 
by two investigators who were unaware of the respective experimental group 
with ImageJ 1.47a (National Institute of Health, Bethesda, USA), a public 
domain, Java™-based image processing and analysis software program. 
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4.7 Determination of fetal surfactant phospholipid 
synthesis (IV) 
Fetal surfactant phospholipid synthesis was determined by labeling for 
surfactant protein B (SP-B), which plays an essential role in alveolar stability 
and thus contributes to the biophysiological function of the lung [Weaver and 
Conkright, 2001; Hawgood et al., 1998]. Thawed frozen sections were 
incubated with PBS containing 1.0% Triton X-100 (Sigma Aldrich Ltd, Arklow, 
Ireland) for 20 min to improve cell permeabilization. In order to prevent 
nonspecific absorption, sections were blocked with 10% normal goat serum 
(Sigma Aldrich, Saint Louis, USA) for 30 min, followed by incubation with 
affinity-purified rabbit polyclonal anti-SP-B antibodies (sc-7702-R, 1:100) 
(Santa Cruz Biotechnology Inc, Santa Cruz, USA) at 4°C overnight. On the 
next day, sections were washed in PBS + 0.05% Tween and incubated with 
Alexa Fluor® 647 goat anti-rabbit secondary antibodies (A21244, 1:200) (Bio-
Sciences Ltd, Dun Laoghaire, Ireland) at room temperature for 30 min. The 
sections were counterstained with DAPI (10236276001, 1:1000) (Roche 
Diagnostics GmbH, Mannheim, Germany) for 10 min to visualize double-
stranded DNA. Following coverslipping with fluorescent mounting medium 
(DAKO Ltd, Cambridgeshire, UK), two investigators unaware of the 
respective experimental group independently evaluated the sections with a 
LSM 700 confocal laser scanning microscope (Carl Zeiss MicroImaging 
GmbH, Jena, Germany). All images were analyzed with ZEN (Carl Zeiss 
MicroImaging GmbH, Jena, Germany), an image processing and analysis 
software program. 
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4.8 Statistical analyses (I-IV) 
Data were analyzed using GraphPad Prism 5 (GraphPad Software Inc, La 
Jolla, USA) and tested for Gaussian distribution with a Kolmogorov-Smirnov 
test. All results are presented as means ± standard error of the mean (SEM). 
Statistical differences between two experimental groups were compared 
using an unpaired Student’s t test when the data had normal distribution or a
Mann-Whitney U test when the data deviated from normal distribution. In 
order to determine any statistical differences between four experimental 
groups, one-way ANOVA with Tukey’s test for post-test analysis was 
performed. A P value < 0.05 was considered as statistically significant. 
4.9 Ethical considerations (I-IV) 
All animal procedures were carried out according to the current guidelines for 
management and welfare of laboratory animals. The experimental protocol 
was approved by the research ethics committee of the Royal College of 
Surgeons in Ireland (Ref. REC668b) as well as by the Department of Health 
and Children (Ref. B100/4378) under the Cruelty to Animals Act, 1876 (as 
amended by European Communities Regulations 2002 and 2005). 
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4.10 Information source and literature-based search (V)
In order to identify all peer-reviewed scientific publications relating to CDH 
research, a comprehensive search strategy was designed for the Web of 
Science™ database (Clarivate Analytics, Boston, USA). This online 
subscription-based research platform, which provides temporal coverage 
from the year 1900 to present, was accessed on 20 June 2017. The following 
linked search terms were used taking into account alternative nomenclature 
for CDH:”congenital* diaphragm* hernia*” OR ”congenital* diaphragm*
defect*” OR “fetal* diaphragm* hernia” OR “pediatric* diaphragm* hernia*” 
OR “foetal* diaphragm* hernia” OR “paediatric* diaphragm* hernia*” OR 
”agenes* diaphragm*” OR ”agenes* hemidiaphragm*” OR “Bochdalek* 
hernia*” OR “Morgagni* hernia*”. A “title” rather than “topic” search was 
performed to determine only the most relevant research items. No language 
restrictions were imposed. Results from 2017 were excluded from the search 
to ensure complete data acquisition because the incorporation of several 
parameters into the database requires a certain time. 
4.10.1 Selection categories and data analysis (V) 
The retrieved data on CDH-related publications was critically evaluated and 
classified with regard to subject category, document type, journal title, 
publication date and language. Total research output of countries, 
institutions, individual authors and collaborative networks was determined 
and systematically analyzed. The “citation report” function was applied to
assess semi-qualitative research aspects including citation rate and h-index. 
The h-index is an established metric, which incorporates a citation index and 
the overall scientific output of authors or institutions, thus quantifying 
importance, impact and significance of individual research contributions 
[Hirsch, 2005]. It can be calculated, if h of all publications received at least h
citations each. In this study, the h-index has also been used to estimate to 
productivity of publishing countries. 
54
The relationship of two or more authors from different countries, who 
contributed to a joint publication, was defined as a cooperation article.
Complete bibliographic data was downloaded as plain text files and extracted 
into an electronic datasheet in a standardized manner. Choropleth mapping 
(i.e. differences in color values to represent geographical data) and network 
diagrams were employed to visualize results.
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5 Results 
5.1 Observational studies (I, II)  
5.1.1 Relative mRNA expression levels of Thy-1 and Adrp in fetal rat 
lungs (I, II) 
As Thy-1 and its downstream target Adrp are both molecular markers 
characterizing LIFs, pulmonary gene expression levels of Thy-1 and Adrp
were analyzed by qRT-PCR. Relative mRNA expression of Thy-1 and Adrp
was significantly downregulated in hypoplastic rat lungs with nitrofen-induced 
CDH on E21.5 compared to controls (Figure 3).
Figure 3  Relative mRNA expression of Thy-1 (a) and Adrp (b) was significantly downregulated 
in fetal rat lungs with CDH-associated PH compared to control lungs (0.09 ± 0.02 vs. 0.22 ± 0.04; 
***P = 0.0002 and 0.08 ± 0.01 vs. 0.23 ± 0.09; ***P = 0.0009, respectively).  
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5.1.2 Thy-1 protein expression in pulmonary LIFs of fetal rats (I) 
In order to confirm the qRT-PCR results, immunoflurescence double staining 
with Thy-1 and ORO was performed to evaluate Thy-1 protein expression in 
pulmonary LIFs on E21.5. Confocal laser scanning microscopy confirmed 
markedly decreased Thy-1 immunoflurescence in this specific subset of 
alveolar fibroblasts in hypoplastic rat lungs with diaphragmatic defects 
compared to controls (Figure 4). 
 
 
Figure 4  Thy-1 expression and lipid content in pulmonary LIFs of fetal rat lungs. 
Immunofluorescence double staining with Thy-1 and ORO demonstrated markedly decreased 
Thy-1 expression and lipid inclusions in this specific subset of alveolar fibroblasts (arrows) in fetal 
rat lungs with CDH-associated PH (b) compared to control lungs (a). Representative cryostat 
sections of fixed lung tissue stained with specific Thy-1 antibodies (yellow staining), ORO (red 
staining) and DAPI (blue staining) are shown (Magnification x40; Scale bars = 75 μm). 
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5.1.3 Adrp protein expression and cytoplasmatic lipid content in 
pulmonary LIFs of fetal rats (I, II) 
To further validate these findings and to identify lipid inclusions in pulmonary 
LIFs, their expression was ascertained on E21.5 by labeling for the functional 
lipogenic marker protein Adrp combined with specific ORO lipid staining. 
Adrp immunoreactivity was strikingly diminished in alveolar interstitial cells of 
lungs with CDH-associated PH compared to controls, which coincided with 
impaired alveolar mesenchymal cell differentiation (Figure 5). Moreover, this 
was associated with fewer cytoplasmatic lipid droplets in interstitial alveolar 
compartments of nitrofen-exposed rat fetus with diaphragmatic defects 
(Figure 6). 
 
 
Figure 5  Adrp protein expression in fetal rat lungs. Adrp immunohistochemistry (arrows) was 
markedly diminished in alveolar interstitial cells of fetal rat lungs with CDH-associated PH (b) 
compared to control lungs (a), as determined by specific labeling for the functional lipogenic 
marker Adrp, which coincided with impaired alveolar mesenchymal cell differentiation. 
Representative cryostat sections of fixed lung specimens labeled with specific Adrp antibodies 
(brown staining) and hematoxylin (blue staining) are shown (Magnification x40; Scale bars = 50 
μm).  
 
58
Figure 6 Cytoplasmatic lipid content in fetal rat lungs. Specific lipid staining with ORO showed 
markedly reduced lipid droplets (arrows) in the alveolar interstitium of fetal rat lungs with CDH-
associated PH (b) compared to control lungs (a). Representative cryostat sections of fixed lung 
tissue are shown (Magnification x40; Scale bars = 50 μm).
 
5.1.4 Pulmonary LIF expression in fetal rat lungs (II)
Following immunofluorescence double staining, confocal laser scanning 
microscopy showed absence of αSMA expression as well as markedly 
reduced lipid inclusions in pulmonary LIFs on E21.5, thus clearly 
demonstrating notably decreased expression of this specific subset of 
fibroblasts in the alveolar interstitium of hypoplastic rat lungs with CDH
compared to controls (Figure 7).
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Figure 7  Pulmonary LIF expression in fetal rat lungs. Confocal laser scanning microscopy 
revealed absence of αSMA expression with markedly reduced lipid inclusions in pulmonary LIFs, 
thus demonstrating a markedly decreased expression of this specific subset of fibroblasts 
(arrows) in alveolar interstitium of CDH-associated PH (b) on E21.5 compared to controls (a). 
Representative cryostat sections of fixed lung specimens double stained with αSMA (green 
staining), ORO (red staining) and DAPI (blue staining) are shown (Magnification x40; Scale bars 
= 50 μm). 
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5.2 In vivo treatment studies with ATRA (III, IV) 
5.2.1 Effect of prenatally administered ATRA on fetal lung-to-body 
weight ratio (IV) 
As fetal body and lung weight is a reflection of overall development, the in 
vivo effect of maternal ATRA application on body and lung weight was 
examined in E21.5 rat fetuses. In nitrofen-exposed fetuses, there was a 
significant increase in lung-to-body weight ratio after prenatal administration 
of ATRA shortly before birth compared to the placebo group (2.14 ± 0.03% 
vs. 1.78 ± 0.05%; P < 0.01) (Figure 8). The difference in lung-to-body weight 
ratio between control and nitrofen-exposed fetuses that only received 
placebo treatment was also statistically significant (2.21 ± 0.03% vs. 1.78 ± 
0.05%; P < 0.0001). 
Figure 8  Effect of maternal ATRA application on fetal lung-to-body weight ratio. 
Prenatal administration of ATRA resulted in nitrofen-exposed fetuses in a 
significantly increased lung-to-body weight ratio compared to the placebo group 
(**P < 0.01, vs. Nitrofen+Placebo; #P < 0.0001, vs. Control+Placebo).
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5.2.2 Effect of prenatally administered ATRA on pulmonary gene 
expression levels of Adrp in fetal rats (III) 
As Adrp is a downstream target of Thy-1 signaling and known functional 
lipogenic marker characterizing LIFs [Schultz et al., 2002], pulmonary gene 
expression levels of Adrp were analyzed on E21.5 by qRT-PCR. Relative 
mRNA expression of pulmonary Adrp was significantly increased in 
Nitrofen+ATRA compared to Nitrofen+Placebo (0.31 ± 0.02 vs. 0.08 ± 0.01; 
P < 0.0001), whereas there were no significant differences between 
Control+ATRA and Control+Placebo (0.24 ± 0.01 vs. 0.21 ± 0.02; P = 
0.1319). 
5.2.3 Effect of prenatally administered ATRA on alveolar protein 
expression of Adrp in fetal rats (III) 
In order to determine whether the increased amounts of Adrp transcripts 
after prenatal treatment with ATRA were also translated to the protein level, 
Adrp expression and distribution were investigated on E21.5 by specific 
labeling with Adrp antibodies directly on pulmonary tissue sections. Light 
microscopy confirmed the qRT-PCR results showing markedly increased 
Adrp immunoreactivity mainly in distal alveolar interstitium of Nitrofen+ATRA 
compared to Nitrofen+Placebo, whereas there were no differences between 
Control+ATRA and Control+Placebo (Figure 9).
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Figure 9  Effect of maternal ATRA application on alveolar protein expression of Adrp in fetal rats. 
Adrp immunoreactivity (arrows) was markedly increased in distal alveolar interstitium of 
Nitrofen+ATRA (d) compared to Nitrofen+Placebo (c), whereas there were no differences 
between Control+ATRA (b) and Control+Placebo (a). Representative cryostat sections of fixed 
lung tissue stained with specific Adrp antibodies (brown staining) and hematoxylin (blue staining) 
are shown (Magnification x40; Scale bars = 100 μm). 
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5.2.4 Effect of prenatally administered ATRA on lipid content and LIFs 
in fetal rat lungs (III) 
The presence of lipid droplets, which are characteristic for pulmonary LIFs 
[Brasaemle et al., 1997], was evaluated by ORO staining directly on tissue 
sections of E21.5 rat lungs. Light microscopy indicated a notably increased 
expression of cytoplasmatic lipid inclusions in alveolar interstitial cells of 
Nitrofen+ATRA compared to Nitrofen+Placebo, whereas there were no 
differences between Control+ATRA and Control+Placebo (Figure 10). 
 
 
Figure 10  Effect of maternal ATRA application on lipid content in fetal rat lungs. Expression of 
cytoplasmatic lipid droplets (arrows) was markedly increased in alveolar interstitial cells of 
Nitrofen+ATRA (d) compared to Nitrofen+Placebo (c), whereas there were no differences 
between Control+ATRA (b) and Control+Placebo (a). Representative cryostat sections of fixed 
lung specimens stained with ORO are shown (Magnification x40; Scale bars = 50 μm). 
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Immunofluorescence double staining for αSMA, which is characteristically 
absent in LIFs [Torday et al., 2003], and ORO was used to assess 
pulmonary LIF expression and localization in E21.5 rat fetuses. Confocal 
laser scanning microscopy demonstrated markedly increased LIFs in 
interstitial compartments of distal alveolar walls of Nitrofen+ATRA compared 
to Nitrofen+Placebo, whereas there were no differences between 
Control+ATRA and Control+Placebo (Figure 11). 
 
 
Figure 11  Effect of maternal ATRA application on pulmonary LIFs in fetal rats. The expression of 
this specific subset of lung fibroblasts (arrows) was markedly increased in interstitial 
compartments of distal alveolar walls of Nitrofen+ATRA (d) compared to Nitrofen+Placebo (c), 
whereas there were no differences between Control+ATRA (b) and Control+Placebo (a). 
Representative cryostat sections of fixed lung tissue double stained with αSMA (green staining), 
ORO (red staining) and DAPI (blue staining) are shown (Magnification x40; Scale bars = 75 μm). 
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5.2.5 Effect of prenatally administered ATRA on alveolarization in fetal 
rat lungs (IV) 
Stereo-/Morphometric analysis of fetal rat lungs revealed a significant 
progression in alveolar development after prenatal administration of ATRA. 
Nitrofen-exposed fetuses that received ATRA application shortly before birth 
showed enhancement of alveolarization on E21.5 (Figure 12), which was 
expressed in a significant increase in RAC (6.66 ± 1.3 per mm2 vs. 5.70 ± 1.2 
per mm2; P < 0.0001) and decrease in MLI (42.44 ± 1.5 μm vs. 45.06 ± 1.3 
μm; P < 0.0001) compared to Nitrofen+Placebo, whereas there was no 
significant differences between Control+Placebo and Control+ATRA (Figure 
13). The differences in RAC (10.05 ± 1.4 per mm2 vs. 5.70 ± 1.2 per mm2; P
< 0.0001) and MLI (41.23 ± 1.6 μm vs. 45.06 ± 1.3 μm; P < 0.0001) between 
control and nitrofen-exposed fetuses that only received placebo treatment 
were each statistically significant. 
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Figure 12  Effect of maternal ATRA application on alveolarization in fetal rat lungs. Prenatal 
administration resulted in a marked increased alveolarization in Nitrofen+ATRA (d) compared to 
Nitrofen+Placebo (c), whereas there were no differences between Control+ATRA (b) and 
Control+Placebo (a). Representative cryostat sections of fixed lung specimens stained with 
hematoxylin (blue staining) and eosin (pink staining) are shown (Magnification x40; Scale bars = 
100 μm). 
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Figure 13  Effect of maternal ATRA application on lung stereo-/morphometry in fetal rats.
Prenatal administration of ATRA resulted in nitrofen-exposed fetuses in a significantly increased 
radial alveolar count (a) and decreased mean linear intercept (b) on E21.5 compared to placebo-
treated lungs  (***P < 0.0001, vs. Nitrofen+Placebo; #P < 0.0001, vs. Control+Placebo).
5.2.6 Effect of prenatally administered ATRA on pulmonary gene 
expression levels of Lep and Lep-R in fetal rats (IV) 
As Lep and its receptor Lep-R are both molecular markers characterizing 
alveolar maturation, pulmonary gene expression levels of Lep and Lep-R
were analyzed by qRT-PCR on E21.5. Nitrofen-exposed lungs of rat fetuses 
that received ATRA application shortly before birth exhibited a significantly 
increased relative mRNA expression of Lep (4.65 ± 0.67 vs. 2.38 ± 0.67; P < 
0.05) and Lep-R (1.73 ± 0.10 vs. 0.83 ± 0.12; P < 0.05) compared to 
Nitrofen+Placebo. 
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5.2.7 Effect of prenatally administered ATRA on alveolar protein 
expression of Lep and Lep-R in fetal rats (IV) 
To further validate whether the increased amounts of pulmonary Lep and 
Lep-R mRNA transcripts after prenatal treatment with ATRA were also 
translated to the protein level, alveolar Lep and Lep-R protein expression 
was evaluated in fetal rat lungs on E21.5 by labeling with specific Lep and 
Lep-R antibodies. Light microscopy confirmed the qRT-PCR results showing 
markedly increased Lep and Lep-R immunoreactivity in interstitial and 
alveolar epithelial cells of Nitrofen+ATRA compared to Nitrofen+Placebo 
(Figure 14). 
 
 
Figure 14  Effect of maternal ATRA application on alveolar protein expression of Lep and Lep-R 
in fetal rats. Prenatal administration of ATRA resulted in nitrofen-exposed fetuses in a markedly 
increased Lep (b) and Lep-R (d) immunoreactivity in interstitial and alveolar cells (arrows) 
compared to placebo-treated lungs (a and c, respectively). Representative cryostat sections of 
fixed lung tissue stained with specific Lep or Lep-R antibodies (brown staining) and hematoxylin 
(blue staining) are shown (Magnification x40; Scale bars = 100 μm). 
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5.2.8 Effect of prenatally administered ATRA on surfactant 
phospholipid synthesis in fetal rat lungs (IV) 
Immunoflurescence staining with SP-B was performed to examine pulmonary 
surfactant production in E21.5 rat fetuses. Confocal laser scanning 
microscopy demonstrated notably increased alveolar SP-B protein 
expression (Figure 15) and significantly increased SP-B count (Figure 16) 
after prenatal administration of ATRA in Nitrofen+ATRA compared to 
Nitrofen+Placebo. 
 
 
Figure 15  Effect of maternal ATRA application on surfactant phospholipid synthesis in fetal rat 
lungs. Prenatal administration of ATRA resulted in nitrofen-exposed fetuses (b) in a markedly 
increased alveolar SP-B staining on E21.5 compared to placebo treatment (a), as determined by 
specific labeling for the surfactant phospholipid marker SP-B. Representative cryostat sections of 
fixed lung specimens stained with SP-B antibodies (red staining) and DAPI (blue staining) are 
shown (Magnification x40; Scale bars = 50 μm). 
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Figure 16  Effect of maternal ATRA application on SP-B count in fetal rat lungs. Prenatal 
administration of ATRA resulted in nitrofen-exposed fetuses in a significantly increased SP-B
count compared to placebo-treated lungs (***P < 0.0001, vs. Nitrofen+Placebo; #P < 0.0001, vs.
Control+Placebo).
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5.3 Scientometric analysis of the global research activity 
(V) 
 
5.3.1 Global publication volume (V) 
A total of 3,669 publications on CDH were identified, originating from 76 
countries (Figure 17). North America and Europe constituted the two 
scientific centers in the field of CDH-related research. In contrast, the vast 
majority of African countries had an extremely low or no scientific output on 
CDH. Globally, the largest number of scientific articles relating to CDH was 
published by the USA [n = 1,250; (34.1%)], the United Kingdom [n = 279; 
(7.6%)] and Canada [n = 215; (5.9%)]. Most CDH papers were written in 
English [n = 3,432; (93.5%)], followed by French [n = 87; (2.4%)] and 
German [n = 81; (2.2%)]. 
 
 
Figure 17  Choropleth mapping visualizing the global publication volume in the field of CDH 
research. 
 
 
72 
 
5.3.2 International research collaborations (V) 
Clinicians and basic scientists in 53 (69.7%) of the identified 76 countries 
that published CDH-related work were involved in international research 
collaborations (Figure 18). The USA combined the highest number of 
cooperation articles on CDH (n = 152), followed by Belgium (n = 115) and 
the Netherlands (n = 93). The most productive collaborative network in the 
field of CDH research was established between the United Kingdom/Belgium 
(n = 53), followed by Belgium/Spain (n = 47) and the United Kingdom/Spain 
(n = 34). Luxembourg (n = 3), Venezuela (n = 2), Dominica, Iceland, 
Indonesia, Malta, Peru, St. Kitts & Nevis, Sudan and Ukraine (n = 1/each) 
only had joint CDH papers, whereas Turkey had with 3/92 (3.3%) the 
smallest percentage of cooperative items in relation to its total output. CDH 
researchers in 23 (30.3%) countries were not involved in any international 
collaborations. Of those, South Korean investigators released the largest 
number of CDH publications (n = 28), followed by authors from Iran (n = 11) 
and Tunisia (n = 8). 
 
 
Figure 18  Network diagram of international collaborations and cooperation publications 
relating to CDH. 
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5.3.3 Citation rate and country-specific h-index (V) 
The 215 identified CDH publications from Canada had the highest average 
citation rate per published item (22.8), followed by articles from the 
Netherlands (20.7) and USA (20.2). The USA had the highest country-
specific h-index in the field of CDH-related research (72), followed by 
Canada (40) and the United Kingdom (38). In contrast, many scientific 
papers from African, Middle Eastern and Eastern European countries 
received extremely few citations and thus these countries frequently had a h-
index of 1 or 0. 
 
 
5.3.4 Most productive research institutions and authors (V) 
All 3,669 scientific publications on CDH were evaluated in relation to their 
institutions of origin and contributing authors. The identified CDH articles 
were affiliated with a total of 2,187 institutions and 10,210 authors. The ten 
most productive CDH research institutions in the world were located in the 
USA, the Netherlands, Belgium, France, Ireland, the United Kingdom and 
Canada (Figure 19a). The ten most productive authors (appearing anywhere 
in the author list) in the field of CDH-related research came from the USA, 
Belgium, the Netherlands, Ireland, Spain and Germany (Figure 19b). 
 
 
Figure 19  Ten most productive institutions (a) and authors (b) in the field of CDH-related 
research. 
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5.3.5 Scientific subject categories and document types (V) 
Subject categories are defined standard categories in the Web of Science™ 
database, which represent general areas of science. These categories were 
distributed by the Journal Citation Reports™ for each scientific journal and its 
publications. Most articles relating to CDH research were assigned to the 
subject category “PEDIATRICS” (n = 1,723), followed by “SURGERY” (n = 
1,474) and “OBSTETRICS/GYNECOLOGY” (n = 449). Other common 
categories were “GENERAL INTERNAL MEDICINE” (n = 370), 
“RADIOLOGY/NUCLEAR MEDICINE/MEDICAL IMAGING” (n = 259), 
“RESPIRATORY SYSTEM” (n = 212), “GENETICS” (n = 188), 
“CARDIOVASCULAR SYSTEM/CARDIOLOGY” (n = 96), 
“RESEARCH/EXPERIMENTAL MEDICINE” (n = 74) and “GASTRO-
ENTEROLOGY/HEPATOLOGY” (n = 66). 
Document types of the 3,669 identified CDH publications were 
classified as 2,576 original articles (70.2%), 494 meeting abstracts and 
proceedings (13.5%), 332 editorials and letters (9.0%), 149 reviews (4.1%) 
and 118 others (3.2%). 
5.3.6 Publication and citation trend (V) 
The first CDH-related paper was published in 1910 and the number of 
subsequent scientific publications increased almost annually, associated with 
a steady increase in citations (Figure 20). Until 1970, there was low 
publication activity, comprising of 161 articles. From 1970 onwards, the 
number of published items increased constantly with a steep rise in the early-
mid 1990s, interrupted by a brief drop in the late 1990s/early 2000s, 
comprising a total of 3,508 articles (i.e. 95.6% of all scientific publications on 
CDH were published after 1970). Overall, authors published 19-fold more 
articles relating to CDH in 2016 than in 1970. Between 1922 and 2016, the 
3,669 identified CDH publications received a total of 51,253 citations and an 
average of 533.9 citations per year (range, 0-3,215). 
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Figure 20  Overall number of CDH publications and received citations in the time span 1900 to 
2016. 
 
 
5.3.7 Notable scientific journals and publications (V) 
All scientific journals listed in the Web of Science™ database were examined 
in regard to their individual output relating to CDH research and citation rates 
of relevant items were determined. The 3,669 CDH-related articles were 
published in 573 different journals with an average citation rate of 14.0 
(range, 0-414) per publication (h-index: 85). The “Journal of Pediatric 
Surgery” was identified as the most productive journal (n = 649), whereas 
“The Journal of Pediatrics” had with 33.1 the highest average citation rate 
per published CDH paper (Figure 21). 
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Figure 21  Ten most productive journals with regard to CDH publications and average citation 
rate per published article. 
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Table 2 lists the ten most-cited articles in the field of CDH research between 
1910 and 2016. 
Table 2  Ten most-cited publications in the field of CDH research. 
Rank Publication
Total 
citations
Citations 
per year
1 Cantrell JR, Haller JA, Ravitch MM. A syndrome of congenital 
defects involving the abdominal wall, sternum, diaphragm, 
pericardium, and heart. Surg Gyn Obstet 1958;107:602-614.
414 6.90
2 Metkus AP, Filly RA, Stringer MD, et al. Sonographic predictors 
of survival in fetal diaphragmatic hernia. J Pediatr Surg
1996;31:148-152.
351 15.95
3 Harrison MR, Keller RL, Hawgood SB, et al. A randomized trial 
of fetal endoscopic tracheal occlusion for severe fetal congenital 
diaphragmatic hernia. N Engl J Med 2003;349:1916-1924.
300 20.00
4 Stege G, Fenton A, Jaffray B. Nihilism in the 1990s: the true 
mortality of congenital diaphragmatic hernia. Pediatrics
2003;112:532-535.
269 17.93
5 Kitagawa M, Hislop A, Boyden EA, et al. Lung hypoplasia in 
congenital diaphragmatic hernia. A quantitative study of airway, 
artery, and alveolar development. Br J Surg 1971;58:342-346.
244 5.19
6 Boloker J, Bateman DA, Wung JT, et al. Congenital 
diaphragmatic hernia in 120 infants treated consecutively with 
permissive hypercapnea/spontaneous respiration/elective 
repair. J Pediatr Surg 2002;37:357-365.
224 14.00
7 Harrison MR, Jester JA, Ross NA. Correction of congenital 
diaphragmatic hernia in utero - 1. The model: intrathoracic 
balloon produces fatal pulmonary hypoplasia. Surgery
1980;88:174-182.
210 5.53
8 Difiore JW, Fauza DO, Slavin R, et al. Experimental fetal 
tracheal ligation reverses the structural and physiological-effects 
of pulmonary hypoplasia in congenital diaphragmatic hernia. J
Pediatr Surg 1994;29:248-257.
209 8.71
9 Lipshutz GS, Albanese CT, Fekdstein VA, et al. Prospective 
analysis of lung-to-head ratio predicts survival for patients with 
prenatally diagnosed congenital diaphragmatic hernia. J Pediatr 
Surg 1997;32:1634-1636.
204 9.71
10 Deprest J, Gratacos E, Nicolaides KH, et al. Fetal tracheal 
occlusion (FETO) for severe congenital diaphragmatic hernia: 
evolution of a technique and preliminary results. Ultrasound 
Obstet Gynecol 2004;24:121-126.
201 14.36
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6 Discussion 
PH is considered to be one of the main reasons of neonatal mortality and 
long-term morbidity in infants with CDH [Keijzer and Puri, 2010; Rottier and 
Tibboel, 2005]. Decades of research have focused on attempts to improve 
lung maturation in these patients, which has led to the widespread use of 
exogenous surfactant, inhaled nitric oxide, high-frequency oscillation and 
ECMO [Garriboli et al., 2012]. However, more recently it became clear that 
these therapeutic options do not significantly reduce CDH-associated 
mortality rates nor provide considerable outcome benefits [Guner et al., 
2018; Snoek et al., 2016; Putnam et al., 2016; Lally et al., 2004]. Due to the 
absence of sufficient lung-protective strategies, most of these newer 
treatment modalities have therefore merely replaced mortality with a higher 
rate of chronic lung disease and impaired neurodevelopment [Madderom et 
al., 2013; Wynn et al., 2013; Rocha et al., 2012]. Despite the necessity to 
find an optimal treatment for lung immaturity in CDH, extensive research in 
the field has not succeeded yet. 
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6.1 Methodology 
The exact pathogenesis of CDH-associated PH remains incompletely 
understood because of the myriad of involved spatiotemporal processes 
comprising multiple, complex molecular and cellular interactions. Based on 
findings from experimental animal studies, it has been demonstrated that 
decreased alveolar formation and reduced synthesis of pulmonary surfactant 
contributes to the development of PH in CDH [Utsuki et al., 2001; Alfonso et 
al., 1996]. Alveolarization and maturation of distal airspaces is an essential 
phase in developing fetal lungs that requires well-coordinated expression of
many regulatory factors, which in turn stimulate alveolar growth and 
surfactant production [Herriges and Morrisey, 2014; Morrisey and Hogan, 
2010; Roth-Kleiner and Post, 2003]. Most of our current understanding about 
this important stage during pulmonary growth and associated changes in 
hypoplastic lungs with diaphragmatic defects has originated from different 
animal models [Chiu, 2014; van Loenhout et al., 2009; Mortell et al., 2006].
In the present work, the well established nitrofen model was used to 
investigate CDH-associated disturbances during alveolar formation, as the 
timing of the diaphragmatic insult and bilateral PH are remarkably similar to 
the human situation [van Loenhout et al., 2009; Beurskens et al., 2007].
However, although maternal exposure of the herbicide nitrofen to pregnant 
rodents during midgestation has been found to result in CDH in 
approximately 70% and PH in 100% of the offspring [Noble et al., 2007], a
major shortcoming of this model is the fact that the potential teratogenic 
effects of nitrofen have not been proven to induce diaphragmatic defects and 
lung hypoplasia in humans so far [Keijzer and Puri, 2010]. Therefore,
collaborative research studies utilizing genome-wide arrays and next 
generation sequencing technics may be more useful to identify potential new 
CDH-related genes in humans. 
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6.2 Role of LIFs as a potential target to enhance fetal 
alveolar development and lung maturation in the 
nitrofen CDH model 
Pulmonary LIFs, which are mainly expressed in the alveolar interstitium and 
have been shown to account for approximately 50% of all resident alveolar 
wall cells in immature lungs [Kaplan et al., 1985], playing a crucial role in 
alveolar development by promoting alveolar epithelial cell differentiation and 
de novo production of surfactant phospholipids [Rehan et al., 2006; Torday 
et al., 2003; McGowan and Torday, 1997]. This specific subset of lung 
fibroblasts normally arises in fetal rat lungs during the late canalicular stage 
of pulmonary development with a significant increase over the last few days 
of gestation [Tordet et al., 1981]. It has been indicated that pulmonary LIFs 
contain large, cytoplasmatic lipid droplets, which enable their histological 
detection within the walls of developing fetal alveoli [Torday and Rehan, 
2011; Brasaemle et al., 1997]. During the onset of alveolarization, these lipid 
inclusions were found to be associated with the expression of Thy-1, a 25-37
kDA heavily N-glycosylated, glycophosphtidylinositol-anchored cell surface 
protein that has recently been revealed as a regulator of alveolar LIF 
differentiation and lipid homeostasis in developing lungs [Varisco et al., 
2012]. Furthermore, LIFs are characterized by a relatively high expression of 
Adrp shortly before birth [Schultz et al., 2002], which is a known downstream 
target of Thy-1 and most pronouncedly expressed in fetal and newborn lungs 
[Londos et al., 1999]. Adrp is a functional lipogenic marker of fully 
differentiated pulmonary LIFs that controls the intracellular uptake of neutral 
lipids in this specific subset of lung fibroblasts and their subsequent transport 
to AECII [Schultz et al., 2002]. Consequently, Adrp reflects the content of 
lipid droplets in alveolar LIFs [Magra et al., 2006] and is also a physiological 
determinant for the synthesis of surfactant phospholipids in AECII [Torday 
and Rehan, 2011]. Treatment strategies aiming to increase the expression of 
pulmonary LIFs therefore represent a promising therapeutic approach to 
enhance fetal alveolar development and thus lung maturation in CDH-
associated PH. 
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In the present study, αSMA and ORO staining was combined to 
evaluate the distribution of LIFs in fetal rat lungs in detail. Given the fact that 
this specific subset of lung fibroblasts is characterized by an absence of 
αSMA expression [Torday et al., 2003], it is not surprising that confocal laser 
scanning microscopy showed absent αSMA immunofluorescence as well as 
markedly reduced lipid inclusions in the alveolar interstitium of CDH-
associated PH compared to controls on E21.5. At first glance, this finding 
may appear in contrast to results from previous studies [Santos et al., 2007; 
Okazaki et al., 1997], which reported no significant differences in αSMA 
staining between hypoplastic lungs and control group in the rat model of 
nitrofen-induced CDH. However, the current experiments focused merely on 
the identification and localization of LIFs in the alveolar walls of fetal rat 
lungs, while other investigators used αSMA staining mainly to analyze 
changes in vascular smooth muscle cells of pulmonary arteries that 
eventually cause PPHN [Jesudason et al., 2006; Taira et al., 1998; 
Yamataka and Puri, 1997]. 
83
6.3 Disruption of Thy-1 signaling and Adrp expression in 
hypoplastic rat lungs with nitrofen-induced CDH is 
associated with an overall reduction of pulmonary LIFs
The present study demonstrated a significant downregulation of pulmonary 
Thy-1 transcripts in fetal rat lungs with CDH-associated PH compared to 
controls, which in turn suggests a disruption of Thy-1 signaling in the nitrofen
model. Immunohistochemistry confirmed this finding by showing a markedly 
decreased Thy-1 protein expression in alveolar LIFs, which was associated 
with an overall reduction of cytoplasmatic lipid droplets in this specific subset 
of lung fibroblasts. Two recent studies [Gosemann et al., 2012; Doi et al., 
2010] have provided additional evidence for this intriguing theory by proving 
that further downstream components of the Thy-1 signaling pathway 
[parathyroid hormone-related protein (PTHrP), PTHrP receptor and 
peroxisome proliferator-acivated receptor gamma] were also significantly 
downregulated in nitrofen-induced hypoplastic lungs during late gestation, 
while their relative mRNA expression peaked normally in control lungs. 
Hence, these discoveries suggest that upregulation of Thy-1 signaling during 
this important stage of fetal lung development may be essential for 
alveolarization and associated distal airway maturation in rats with CDH-
associated PH. Moreover, qRT-PCR revealed a significant reduction of 
pulmonary Adrp transcripts, which was further validated by specific 
immunohistochemical evaluation illustrating strikingly diminished Adrp 
immunoreactivity in alveolar LIFs. Taken together, these results verified that 
the quantitative decrease in pulmonary mRNA expression of Thy-1 and Adrp
in the nitrofen rat model was for the most part certainly also translated to the 
protein level. Immunofluorescence double staining ultimately confirmed an 
overall reduction of LIFs in the alveolar interstitium of CDH-associated PH 
with markedly reduced lipid inclusions, thus suggesting an impaired alveolar 
lipid homeostasis and abnormal LIF functioning in nitrofen-exposed rat lungs 
during the critical time period of fetal alveolarization and alveolar maturation. 
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6.4 Molecular and cellular effects of prenatally 
administered ATRA on pulmonary hypoplasia in the 
nitrofen CDH model 
Because most newborn infants with CDH die primarily of respiratory failure 
secondary to severe PH, any therapeutic approach should be focused on 
reducing PH and promoting lung growth. Retinoids are known to play a key 
role during lung morphogenesis [Maden, 2004], including formation of 
primordial alveoli and maturation of distal airspaces [Simon and Mariani, 
2007; Maden and Hind, 2004; McGowan et al., 2000; Massaro and Massaro, 
1996]. Although it is widely accepted that disruption of retinoid signaling 
contributes to the pathogenesis of hypoplastic lungs and diaphragmatic 
defects [Coste et al., 2015; Clugston et al., 2010b; Montedonico et al., 
2008b; Nakazawa et al., 2007; Mendelsohn et al., 1994], most studies have 
only focused on the severity of CDH along with possible reductions in the 
incidence by administration of vitamin A and its derivates [Babiuk et al., 
2004; Thébaud et al., 1999]. Prenatal application of ATRA, which is one of 
the most biologically active metabolites of vitamin A within the retinoid 
signaling pathway, has been demonstrated to accelerate the proliferation of 
alveolar cells and thus having the potential to attenuate PH in nitrofen-
induced CDH [Sugimoto et al., 2008]. However, the exact molecular and 
cellular effects of ATRA treatment on fetal alveolar growth remain poorly 
understood. 
6.4.1 Effects of maternal ATRA application on fetal lung-to body 
weight ratio, Adrp signaling and LIF expression in hypoplastic rat 
lungs with nitrofen-induced CDH 
We observed in this study that in vivo administration of ATRA resulted in a 
significantly increased lung-to-body weight ratio compared to placebo 
treatment. Furthermore, mRNA transcripts of Adrp, a known downstream 
target of Thy-1 signaling and functional lipogenic marker characterizing 
pulmonary LIFs [Schultz et al., 2002], were significantly increased in 
hypoplastic lungs of nitrofen-exposed fetuses after prenatal application of 
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ATRA, which again was associated with markedly increased Adrp 
immunoreactivity mainly in the distal alveolar interstitium. In addition, the 
occurrence of cytoplasmatic lipid droplets in alveolar interstitial cells was 
notably increased in nitrofen-induced hypoplastic lungs after prenatal 
administration of ATRA compared to placebo treatment, which was 
accompanied by a marked increase of LIFs in the mesenchymal and 
interstitial compartments of distal alveolar walls.  
6.4.2 Effects of maternal ATRA application on fetal alveolarization and 
maturation in hypoplastic rat lungs with nitrofen-induced CDH 
In the alveolar region of immature lungs, ATRA has been shown to be stored 
in LIFs [Dirami et al., 2004; Shenai and Chytil, 1990; Okabe et al., 1984] and 
is utilized to regulate the expression of many retinoid-responsive genes, 
which in turn initiates the formation of alveolar septa, proliferation of AECII 
and associated synthesis of pulmonary surfactant proteins [Massaro and 
Massaro, 2010; Chytil, 1996; Mangelsdorf and Evans, 1995]. As normal 
functioning LIFs are able to synthesize ATRA [McGowan et al., 1995], it was 
not surprising that we did not find any structural or morphological differences 
between Control+ATRA and Control+Placebo. Stereo- and morphometric 
analysis of fetal lungs, a well established technique that allows accurate 
study of forming alveoli [Bolender et al., 1993], has revealed a significant 
progression in alveolar development after prenatal administration of ATRA. 
Nitrofen-exposed fetuses that received ATRA application shortly before birth 
showed enhanced radial alveolar count and decreased mean linear intercept 
compared to placebo treatment. These findings are consistent with previous 
studies, demonstrating that prenatal administration of ATRA stimulates 
alveolarization in nitrofen-induced hypoplastic lungs [Montedonico et al., 
2008a; Montedonico et al., 2006]. Taken together, this highlights that ATRA 
is not only essential for alveolar growth, but also has the potential to rescue 
failed alveolar formation [Massaro and Massaro, 2003]. 
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As there were no significant differences between nitrofen-exposed 
fetuses that had CDH compared to those who did not have CDH, our results 
confirmed that the therapeutic effects of prenatal treatment with ATRA occur 
independently of the diaphragmatic defect. However, it remains unclear 
whether ATRA has a direct effect on AECII or may function indirectly through 
a mechanism involving epithelial-mesenchymal interactions [Schuger et al., 
1993]. 
6.4.3 Effects of maternal ATRA application on fetal Lep signaling and 
synthesis of surfactant phospholipids in hypoplastic rat lungs 
with nitrofen-induced CDH 
Lep has been found to be critically involved in the regulation of distal airway 
development [Huang et al., 2008]. The lungs are one of the few organs in the 
fetus that express Lep and its functional receptor Lep-R [Bergen et al., 2002], 
which are mutually expressed by pulmonary LIFs and AECII [Torday et al., 
2002]. The expression of Lep and Lep-R has been shown to arise just before 
the onset of AECII maturation, beginning during the late canalicular stage of 
fetal lung development with a significant increase over the last few days of 
gestation [Henson et al., 2004; Torday et al., 2002]. In a recent study, it has 
been demonstrated that Lep upregulates the intracellular expression and 
extracellular secretion of surfactant proteins in AECII [Chen et al., 2013]. 
Additionally, Lep-deficient mice exhibit decreased alveolarization with 
reduced pulmonary surfactant phospholipid synthesis [Tankersley et al., 
1996]. Lep has been reported to increase the maturation of AECII and 
expression of surfactant protein B [Kirwin et al., 2006], which is accompanied 
by an increase in fetal lung weight. These findings highlight the important 
role of Lep and Lep-R during prenatal lung growth by promoting alveolar 
epithelial cell differentiation and de novo surfactant production, suggesting 
them as potential physiological markers of fetal lung maturity [Chen et al., 
2013; Kirwin et al., 2006]. 
87
Previous studies have indicated that Lep and Lep-R expression in 
developing lungs is regulated by retinoid signaling [McGowan et al., 1995]. In 
this way, ATRA may promote alveolar development by accelerating the 
differentiation and subsequent proliferation of AECII [Belloni et al., 2000]. In 
the present study, it was found that mRNA transcripts of Lep and Lep-R were 
significantly increased in fetuses with nitrofen-induded PH after prenatal 
administration of ATRA compared to placebo treatment. This work also 
demonstrated that Lep and Lep-R immunoreactivity were markedly increased 
in interstitial and alveolar epithelial cells of nitrofen-exposed fetuses after 
maternal ATRA application compared to placebo treatment, which was 
accompanied by a notably increased SP-B expression in AECII. These 
results confirmed that the quantitative increases in Lep and Lep-R mRNA 
transcripts were translated to the protein level, thus indicating that ATRA 
upregulates Lep signaling in nitrofen-induced hypoplastic rat lungs, which in 
turn stimulates the synthesis of pulmonary surfactant phospholipids. 
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6.5 Use of retinoids during pregnancy 
The use of retinoids during pregnancy is controversial and currently 
restricted by the Food and Drug Administration because of its teratogenic 
side effects on various developmental aspects of the embryo [Desai et al., 
2007]. For instance, birth defects induced by ATRA embryopathy may 
include central nervous system abnormalities (e.g. facial nerve palsy, 
microencephaly, hydrocephalus), external ear abnormalities (e.g. microtia), 
cardiovascular abnormalities (e.g. transposition of the great vessels, 
hypoplastic left heart syndrome, ventricular septal defects, tetralogy of 
Fallot), craniofacial dysmorphia (e.g. midface hypoplasia, cleft palate and 
lip), eye abnormalities (e.g. ocular hypertelorism), thymus gland 
abnormalities and bone abnormalities (e.g. syndactyly) [Nau 2001; Lammer 
et al. 1985]. However, it has been reported that pregnant women with acute 
leukemia have been successfully treated with ATRA during the second and 
third trimester of pregnancy with no adverse effects on the newborn [Agarwal 
et al., 2015; Valappil et al., 2007]. This allows a possible time window for its 
use in pregnant women during late gestation when alveolarization of fetal 
lungs begins.  
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6.6 Scientometric analysis 
 
Between 1910 and 2016, a total of 3,669 publications on CDH were indexed 
in Web of Science™ database, originating from 76 countries. The absolute 
number of CDH papers has increased nineteen-fold since the 1970s, 
associated with an equally steep increase of citations and replicating the 
same trend as shown in previous scientometric studies on other pediatric 
conditions [Friedmacher et al., 2019; Schöffel et al., 2017]. Advances in 
postnatal resuscitation and introduction of new therapeutic strategies in the 
1990s and 2000s, respectively, most likely contributed to the steep increase 
of CDH research in these two decades. Not surprisingly, only a small number 
of North American and European countries were responsible for the majority 
of CDH-related research, which not only generated most of the scientific 
articles, but also papers high in quality. Of these, the USA, Canada, the 
United Kingdom, France and the Netherlands were the five leading countries 
with regard to the total number of CDH publications, average citation rate 
and h-index. This mirrors the worldwide trend for a greater volume of 
scientific articles to originate from high-income countries [Groneberg-Kloft et 
al., 2008; Braun et al., 1995], and further, for authors from these countries to 
dominate key roles in authorship. In comparison, the lack of publications 
from low- and middle-income countries reflects a pattern in all fields of 
medicine: that survival of infants with serious conditions such as CDH is 
often not feasible in countries with low resources or in healthcare systems, 
where medical professionals are too busy with clinical pressures to commit 
time to research. As significant progress cannot be made by a single 
researcher, there is currently a global movement in science towards 
strategically designed national or international collaborations in order to 
improve overall patient care [Greene, 2007]. This is particularly relevant for 
rare disorders like CDH as shown by the increasing number of cooperation 
papers and collaborative networks in this field. 
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The most productive collaborative network on CDH was established 
between the United Kingdom and Belgium. These findings can partly be 
explained by the efficient and well-funded academic structure in both 
countries, allowing leading experts more frequently to cooperate with their 
international colleagues [Wagner and Jonkers, 2017; Adams, 2013]. All of 
the most productive institutions and authors were either based in North 
America or Europe.
What have been the topics of the most-cited CDH work so far? Four 
out of the ten most-cited articles were directly linked with the intriguing 
concept of in-utero intervention for fetuses with CDH, reporting pioneering 
work from its experimental beginnings, subsequent evolution of this 
technique and a randomized controlled trial. Although there is currently 
insufficient evidence to recommend FETO as a part of routine clinical 
practice [Grivell et al., 2015], a few specialized fetal medicine centers in 
Europe, North and South America successfully perform this procedure 
[Persico et al., 2017; Belfort et al., 2017; Ruano et al., 2012; Dekoninck et 
al., 2011]. Recently, it has been reported that FETO improves neonatal 
survival in CDH fetuses with severe PH compared with standard perinatal 
management [Araujo Júnior et al., 2017; Al-Maary et al., 2016]. Today, FETO 
results in a survival rate of 50% to 60% [Deprest et al., 2014a]. Further 
results from ongoing international randomized trials are anticipated in the 
near future [Deprest et al., 2014b]. Two further papers dealt with prenatal 
predictors for postnatal CDH survival. With the advent of routine maternal 
ultrasound scanning, CDH can now be diagnosed prenatally in up to 60% of 
cases [Benachi et al., 2014]. Nowadays, the observed-to-expected lung 
area-to-head circumference ratio measured on 2D ultrasonography is 
routinely used by fetal medicine centers around the world as a good indicator 
of neonatal prognosis and chronic lung disease in survivors with CDH [Senat 
et al., 2018; Snoek et al., 2017]. Other valuable prognostic parameters are 
extent of liver herniation and observed-to-expected fetal lung volume on 
magnetic resonance imaging [Russo et al., 2017; Kastenholz et al., 2016].
However, gestational age at diagnosis should be taken into account when 
estimating postnatal morbidity and mortality [Bouchghoul et al., 2015].
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Other highly cited themes were: CDH-associated mortality, pulmonary 
hypoplasia and lung-protective therapies. During the last two decades, CDH 
survival rates have slightly but significantly improved [Morini et al., 2017].
Whereas some specialized centers have reported survival rates of close to 
90%, pooled results from the CDH Study Group indicated that today’s overall 
survival rate is approximately 70% [Harting and Lally, 2014]. Defective lung 
alveolarization appears to be a common and potentially actionable 
phenotype in both patients and animal models of CDH [Donahoe et al., 
2016]. These findings have revealed opportunities for the development of 
novel targeted treatment options, particularly in the pre- and postnatal 
stages, when therapeutic drugs combined with appropriate ventilation 
strategies and ECMO can have maximum clinical impact on surviving 
patients. 
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6.7 Limitations 
One of the main limitations of this study was the use of a toxicologically 
introduced animal model due to lacking access to postmortem tissue from a 
human biobank. Although the nitrofen model is a well-established part of 
modern CDH research that has provided important insights into the 
underlying pathogenesis and associated pathophysiological alterations in 
pulmonary development, the potential teratogenic effects of this herbicide 
have never been proven to play a role in human cases. As some strains of 
rodents appear to have a higher susceptibility to nitrofen than others, which 
for instance makes its application difficult to investigate in genetically 
modified mice [Beurskens et al., 2007], pathogen-free Sprague-Dawley rats 
were used to achieve the highest possible rate of diaphragmatic defects and
bilateral PH in the offspring. Even though the fundamental mechanisms by 
which these changes are induced in this CDH model are not fully 
understood, disturbances of the retinoid signalling pathway appear to be very 
likely [Montedonico et al., 2008b; Greer et al., 2003]. 
 Another noteworthy limitation of this study was the fact that 
differences in pulmonary Thy-1, Adrp, Lep, Lep-R and SP-B protein 
expression between the experimental groups were only quantified by 
immunohistochemical staining of representative tissue sections. A major 
problem with Western blot analysis is not the method itself, but the 
availability of high-quality antibodies. Despite all being affinity-purified, none 
of the tested commercial antibodies provided accurate results with regard to 
detection of specific protein levels. This is a known issue with this technique 
[Gilda et al., 2015], why the present study mainly focused on the precise 
evaluation of the cellular protein expression. 
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The main limitations of the scientometric analysis was most likely related to 
the used search engine. Although the Web of Science™ database is a well-
established platform in citation analysis and one of the most comprehensive, 
accurate and unbiased resources for literature searching, not all journals, 
institutions or individual authors that published CDH-related research are 
necessarily listed. The use of other search engines such as 
PubMed/MEDLINE would likely have resulted in marginally different figures. 
Additionally, the choice of database may have caused a potential language 
bias towards scientific articles from English-speaking countries [Van 
Leeuwen et al., 2001] and it is also known that authors and reviewers tend to 
be biased towards their native language in their citation practice [Link, 1998; 
Campbell, 1990]. As the applied search strategy was based on a title rather 
than a topic search to identify all papers which focused primarily on CDH 
research, a few relevant research items may not have been recognized by 
the automated computer search. Another possible bias may be the analysis 
of citation frequency and h-index as measures of scientific quality rather than 
using journal impact factors as a surrogate [Garfield, 2001]. In turn, it must 
be considered that self-citation by authors can considerably manipulate the 
h-index. Unfortunately, the Web of Science™ database does not provide a 
separate function for this type of large dataset, which would allow calculation 
of the h-index excluding self-citations. Nevertheless, this metric is a proven 
tool to compare different countries, institutions and authors working in one 
specific field [Bartneck and Kokkelmans, 2011]. 
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6.8 Future considerations 
A sound understanding of the etiology and pathogenesis of CDH together 
with PH and PPHN is fundamental in order to prevent these children from the 
devastating sequelae of this congenital malformation. Recent advances in 
prenatal intervention by minimally invasive techniques such as FETO and 
regenerative tissue engineering combined with stem cell therapy offer 
encouraging potential for future treatment strategies [De Coppi and Deprest, 
2017; Shieh et al., 2017; Al-Maary et al., 2016; DeKoninck et al., 2015; 
Jeanty et al., 2014; Di Bernardo et al., 2014; Deprest et al., 2014a; Pederiva 
et al., 2013; De Coppi and Deprest., 2012; Deprest and De Coppi, 2012]. 
Translational research therefore represents an essential element in our quest 
for new treatment options for CDH-associated PH, which will mainly depend 
on multi-institutional and international collaborations [Lally and Skarsgard, 
2017]. However, investigations of novel medical therapies and 
pharmaceutical compounds that have the ability to arrest or reverse PH in 
animal models of CDH require the application of standardized research 
methodologies [Eastwood et al., 2015]. The experiments performed in this 
work have allowed us to identify pulmonary LIFs as a potential target for 
prenatal treatment with ATRA to improve alveolar development in 
hypoplastic rat lungs with nitrofen-induced diaphragmatic defects. Further 
functional studies will need to be carried out in order to get a more 
comprehensive scientific knowledge of the underlying molecular and cellular 
effects of ATRA application during fetal alveolarization as well as the impact 
on the involved epithelial-mesenchymal interactions. Additional points for 
future research studies could be isolation, in vitro co-culture with ATRA and
subsequent transplantation of “retinoic acid-enriched” pulmonary LIFs. To 
test the impact of this modified subset LIFs on immature lungs, one could 
create fluorescent-labeled cells and administer them to nitrofen-exposed rat 
fetuses prenatally. Probably the best way of administration with direct 
delivery of these cells to the hypoplastic lungs would be endoscopical 
microinjection into the trachea followed by FETO. Afterwards, pulmonary 
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tissue could be isolated and microscopically investigated for morphology and 
localization of the labeled LIFs. Moreover, isolated lung cells could be sorted 
by fluorescence-activated cell sorting to determine their differentiation 
pattern. Another option could be the injection of ATRA-treated and 
fluorescent-labeled LIFs into the trachea of nitrofen-exposed lung explants. It 
may be possible to follow these cells for a certain amount of time using live 
imaging combined with confocal laser scanning microscopy and study their 
individual behavior in vitro over several hours. 
International multicenter consortiums and national research networks 
have addressed many critical knowledge gaps pertaining to CDH care. Most 
importantly, they have identified variability in both CDH practice and outcome 
among participating centers. Using combined data from these groups, 
national or international consensus guidelines for multidisciplinary CDH 
treatment may be produced to standardize best practices for patients with 
CDH, from prenatal diagnosis to hospital discharge, based on the best 
available clinical evidence. In addition, collaborations with global initiatives 
such as CDH International may help to foster further research activities and 
strengthen support groups.
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7 Conclusions
PH, characterized by a significantly decreased number of terminal airway 
generations and alveolar immaturity, is one of the main reasons for the 
potential life-threatening respiratory insufficiency in newborns with congenital 
diaphragmatic defects, leading to high neonatal mortality and long-term 
morbidity. The objectives of this dissertation were to investigate the 
underlying molecular and cellular alterations in pulmonary LIFs and AECII at 
the end of gestation in the nitrofen-induced rat model of CDH, which form the 
basis for a therapeutic approach with ATRA. Alterations in Thy-1 signaling 
and its downstream target Adrp in hypoplastic rat lungs with toxicologically 
induced diaphragmatic defects were systematically evaluated in two 
observational studies, and resulting changes in the amount of cytoplasmatic 
lipid droplets in LIFs and overall expression of this specific subset of lung 
fibroblasts were examined. The effects of prenatally administered ATRA on 
fetal alveolarization and surfactant phospholipid synthesis in nitrofen-
exposed rat fetuses with CDH-associated PH were assessed in two in vivo
treatment studies using molecular genetic, immunohistochemical/-
fluorescence and stereo-/morphometric analysis techniques. Based on the 
results of these studies, the following conclusions can be drawn: 
1. Disruption of Thy-1 signaling in hypoplastic rat lungs leads, through a 
disturbed uptake of neutral lipids into pulmonary LIFs at the end of 
fetal gestation, to markedly reduced cytoplasmatic lipid content in this 
specific subset of lung fibroblasts, which is associated with an 
impaired alveolar development and PH in the nitrofen-induced CDH 
model. (I) 
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2. Decreased pulmonary Adrp expression during late gestation is 
accompanied by an overall reduction of LIFs in hypoplastic rat lungs, 
thereby suggesting that disruption of Adrp-regulated alveolar 
mesenchymal cell differentiation and lipid homeostasis in nitrofen-
exposed fetuses with diaphragmatic defects may cause impaired 
alveolar formation and eventually PH through disturbed LIF 
functioning. (II) 
3. Maternal application of ATRA shortly before birth increases the fetal 
expression of LIFs and alveolarization in hypoplastic rat lungs with 
nitrofen-induced CDH, suggesting that ATRA may have a therapeutic 
potential in attenuating CDH-associated PH by stimulating alveolar 
formation and distal airway maturation through increased expression 
of pulmonary LIFs. (III) 
4. Prenatally administered ATRA upregulates Lep signaling in 
hypoplastic rat lungs, which in turn increases de novo production of 
pulmonary surfactant in nitrofen-exposed fetuses with diaphragmatic 
defects and thus may reduce experimentally induced PH by increased 
synthesis of surfactant phospholipids at the end of gestation. (IV)
In addition, this study draws the first detailed map of the global CDH 
research architecture based on an in-depth analysis of the scientific 
output from 1910 to 2016: 
5. During this time span, CDH-related research has progressed from 
simple empirical observations to accumulation of best clinical 
evidence, becoming much more multidisciplinary with main research 
endeavors concentrating in a few high-income countries. Great strides 
in basic science and biomedical technology have contributed to a 
number of revolutionary new discoveries in the pathogenesis and 
pathophysiological mechanisms of CDH.  
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Collaborative research has led to substantial progress in prenatal 
diagnostics and interventions, implementation of standardized 
neonatal treatment protocols and most recently regenerative medicine 
therapy. All these advances hold now the promise of improving CDH 
patient care and outcome in the 21st century. International 
collaborations should therefore be strengthened to allow further 
evolution in this field. (V) 
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